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ABSTRACT 
INCIDIENCE OF SUBCLINICAL HYPOTHYROIDISM IN PATIENTS 
WITH TYPE 2 DIABETES MELLITUS AND ITS EFFECTS ON HbA1C 
AND LIPID PROFILE 
Arvind Krishnakumar1, R. Penchalaiah2. P Dharmarajan3 
INTRODUCTION: There is a significant prevalence of thyroid disorders in 
patients with diabetes mellitus, the most common being subclinical 
hypothyroidism. The co-existence of subclinical hypothyroidism may alter the 
glycemic profile and lipid profile that is expected in these patients. 
AIM: To determine the incidence of Subclinical Hypothyroidism in patients with 
Type 2 Diabetes Mellitus. Additionally, to evaluate HbA1C and lipid profile in 
patients having subclinical Hypothyroidism and Type 2 Diabetes Mellitus and 
compare with those having only type 2 Diabetes Mellitus. 
MATERIALS AND METHODS: Two hundred patients above 40 years 
diagnosed to have Diabetes Mellitus were subjected to Short Relevant History 
and Physical Examination as per the questionnaire. Liver and renal function tests, 
fasting thyroid profile and fasting lipid profile were taken for all patients. Those 
who had an abnormal liver or renal function test were excluded.  
 
 
1. Post Graduate, General Medicine, Institute of Internal Medicine, RGGGH.  
2. Professor of Medicine, Institute of Internal Medicine, RGGGH, Chennai.  
3. Director and Professor, Institute of Diabetology, RGGGH, Chennai. 
RESULTS: Subclinical Hypothyroidism was present in 12 percent of cases. Four 
percent had overt hypothyroidism. Females were significantly higher in 
proportion than males among those who had subclinical hypothyroidism. The 
presence of subclinical hypothyroidism was not significantly related to higher 
levels of HbA1C. The mean HbA1C in the groups with and without subclinical 
hypothyroidism were 7.93 and 8.53% respectively. There was no significant 
correlation between duration of diabetes and presence of subclinical 
hypothyroidism. There was no significant effect on Total and LDL cholesterol, 
and HDL cholesterol, in patients with subclinical hypothyroidism. There was a 
significantly higher prevalence of hypertriglyceridemia (13.7% versus 79.2%), 
and the mean value of serum triglyceride level was 184.4 md/dL in patients with 
subclinical hypothyroidism, versus 151.3 mg/dL among those with only diabetes.  
CONCLUSION: There is a significant increase in the incidence of subclinical 
hypothyroidism in patients with type 2 diabetes mellitus and this increase is 
associated with a significant rise in the triglyceride levels. There is no correlation 
between HbA1C, total cholesterol, and LDL and HDL cholesterol with presence 
of subclinical hypothyroidism.  
KEY WORDS: Subclinical Hypothyroidism, type 2 diabetes mellitus, lipid 
profile, HbA1C. 
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INTRODUCTION 
 Two of the most common endocrinological diseases are Diabetes and 
Hypothyroidism. Diabetes mellitus is a disorder of glucose metabolism 
wherein the digested carbohydrates are not metabolised either due to an 
absolute or relative lack of the hormone insulin, that is derived from the 
pancreas, or due to a relative peripheral resistance for glucose uptake in 
tissues like the liver, adipose tissue, and skeletal muscle. Hypothyroidism 
refers to an absolute or a relative deficiency in the thyroid hormones. 
Diabetes mellitus is diagnosed using either Random, fasting, or post prandial 
plasma glucose levels, or with Glycated haemoglobin (HbA1c) levels in a 
patient. Hypothyroidism may or may not present with signs and symptoms 
pertaining to the disease. Whether clinically apparent or not, Hypothyroidism 
is basically a biochemical diagnosis, done with the help of thyroid function 
tests. Hypothyroidism can be primary, wherein the defect is in the thyroid 
gland per se, or secondary, wherein the thyroid gland fails to function due to 
lack of, or an abnormal, stimulation by the pituitary hormone thyrotropin 
(TSH). Primary diseases are more common than secondary. Hypothyroidism 
may be subclinical or overt. Since majority of the thyroid hormone 
triiodothyronine (T3) is formed from peripheral conversion of the thyroid 
hormone thyroxin (T4) in the tissues, its level in plasma is minimal, and 
measurement of serum T3 in plasma proves to be a difficult task. Hence, 
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thyroid gland dysfunction is diagnosed mainly using two parameters – Serum 
free T4 and serum Thyrotropin (Thyroid Stimulating Hormone; TSH) levels. 
 Subclinical Hypothyroidism is diagnosed in the presence of an elevated 
serum TSH with a normal Serum free T4 whereas overt Hypothyroidism is 
diagnosed when there is an elevated serum TSH with decreased free T4. 
Subclinical Hypothyroidism may be found in 6-8% women and 3% men. The 
annual risk of developing subclinical Hypothyroidism is about 4% when 
there is an associated positive TPO antibody. 
 There is a significantly higher proportion of individuals who suffer 
from thyroid dysfunction in the diabetic population when compared to the 
general population, the most frequent pattern being subclinical 
Hypothyroidism, and these thyroid disorders are more prevalent in women 
than in men. 
 Both Hypothyroidism and Diabetes alter lipid levels and are the 
leading causes of dyslipidemia in the current era. However the pattern of 
altered lipid profile varies in the two diseases. Whereas Diabetes causes 
abnormalities primarily in High density lipoprotein (HDL) fraction of serum 
cholesterol, Hypothyroidism primarily affects the Low density lipoprotein 
(LDL) cholesterol. Both disorders can cause an elevation in the serum 
triglyceride level. It is important to realise these altered lipid profiles in the 
above two diseases as they pose a significant risk for atherosclerotic 
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progression and adverse cardiac and vascular outcomes in an individual. 
However, the lipid profile pattern in patients suffering from both Diabetes 
and Subclinical Hypothyroidism has not been studied extensively and 
remains controversial.  
 Thyroid hormones, in simple terms, act on various tissues of the body, 
to maintain thermogenesis, energy expenditure, and other metabolic aspects 
of the human body. Some of the biochemical properties and mechanisms of 
actions of thyroid hormones are very similar to those of the catecholamines 
of the autonomic nervous system. Therefore, thyroid dysfunction in a person 
is likely to alter many metabolic activities in the body. One of the major 
metabolic pathways that is primarily affected in thyroid dysfunction is that of 
glucose. Thyroid hormones regulate glucose absorption from the gut, and 
there is a documented reduction in absorption in hypothyroid patients, 
therefore one expects a decreased glucose level in these patients. But this is 
not so. There are many factors that increase the glucose levels in hypothyroid 
individuals as well. These include an increased peripheral resistance to 
insulin due to an increase in adipose tissue mass, a decreased expression of 
glucose receptors in the peripheral tissues, and many more, including altered 
gene expression for insulin hormone. Hence, the glycemic control in 
diabetics with Hypothyroidism (overt and subclinical) may not be good 
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despite strict dietary and lifestyle modifications, and there are conflicting 
reports regarding this observation. 
 The consequences of Hypothyroidism are many, majority of them 
having an effect over the cardiac and vascular system, and many 
complications overlap with the microvascular and macrovascular 
complications of Diabetes. It also becomes a significant comorbid condition 
that hampers the proper management of Diabetes, posing to be a burden for 
the patient and the doctor. It has also been proved that these consequences 
can occur in individuals with subclinical Hypothyroidism as well. It is 
therefore, very important to screen for and detect type 2 Diabetes mellitus 
patients who have a coexisting subclinical Hypothyroidism and treat them 
accordingly. 
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AIMS AND OBJECTIVES 
AIM: 
To determine the incidence of Subclinical Hypothyroidism in patients 
with Type 2 Diabetes Mellitus. 
 
OBJECTIVES: 
1. To evaluate HbA1C in patients having Subclinical Hypothyroidism 
and Type 2 Diabetes Mellitus and compare with those having only type 
2 Diabetes Mellitus. 
2. To evaluate Lipid profile in patients having Subclinical 
Hypothyroidism and Type 2 Diabetes Mellitus and compare with those 
having only type 2 Diabetes Mellitus 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
The term ‘Diabetes’ was derived in the second century, coined by 
Aretaeus (AD 30-90) of Cappadocia. He derived it from the Greek words 
‘dia’ and ‘bianeon’ meaning 'through' and ‘to go’ respectively. The words 
described a siphon that described polyuria. 
Diabetes mellitus was also described in the history of Indian literature 
in the Sanskrit scriptures of Charaka, Susruta and Vaghbata back in the  
5th and 6th century BC. They described the sweet taste of urine in polyuric 
patients and the disease was termed ‘Madhumeha’. They even differentiated 
the disease into two forms, one affecting older people and who are obese, and 
the other affecting thin and young people who do not survive long. This 
description correlated well with the current classification of type 1 and type  
2 Diabetes. The term ‘honey urine’ as described in Indian literature referred 
to the urine of diabetic individuals that was clear, colourless and sweet. 
The thyroid gland was first observed by Galen, who initially thought it 
to be an organ that provided fluid for lubricating the larynx. The term 
‘thyroid’ is a Greek terminology coined by Wharton, meaning ‘Shield’, who 
considered it a gift of nature to females to give the neck a more beautiful 
look.  
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The thyroid gland was first described by Andrecos Vesslius as ‘two 
glands on each side of the laryngeal root which are flesh coloured, large 
fungus like, and covered with blood vessels’ 
The isthmus of the thyroid gland was discovered by Eustachius, while 
Wharton discovered the anatomical site, weight and size in his book 
Adenographia. 
In 1915, a group of physicians in the Mayo Clinic led by Dendall 
isolated the thyroid hormone thyroxine for the first time, but it was 
Harrington in 1925 who first determined the chemical constitution of the 
hormone, and discovered a method of in vitro synthesis of the same.  
DIABETES MELLITUS 
Diabetes Mellitus is a group of diseases that share the common 
metabolic defect of hyperglycemia1. These diseases differ mainly in the 
manner in which they produce hyperglycemia. The mechanisms may be 
genetic, acquired, or environmental. Eventually this leads to decreased 
secretion of insulin from the pancreas, decreased utilization of glucose in the 
peripheral tissue and increased hepatic production of glucose 
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Diabetes mellitus can be broadly classified into  
Type 1 Diabetes 
Type 2 Diabetes 
Gestational Diabetes mellitus 
Other specific types of Diabetes2 
DIAGNOSING DIABETES MELLITUS 
Diabetes Mellitus may be suspected clinically when a patient presents 
at the clinic with classical symptoms of hyperglycemia (blurry vision, 
increased urine output, thirst, and a recent onset weight loss) and has a 
random plasma glucose value of 200 mg/dL or higher. 
Other diagnostic criteria have been developed based upon the risk for 
developing retinopathy and the observed association between glucose levels. 
Fasting plasma glucose values more than or equal to 126 mg/dL, Glycated 
haemoglobin A1C values more than or equal to 6.5 percent, and two-hour 
post oral glucose challenge values of more than or equal to 200 mg/dL are 
associated with an increased prevalence of retinopathy3.  
Not surprisingly, since the different measures of glycemia represent 
different physiologic phenomena, each of the measures will identify different 
proportions of the population with Diabetes. For example, the shift from 
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using the fasting plasma glucose to using A1C to diagnose Diabetes may 
decrease the proportion of patients identified as having Diabetes4-6. As an 
example, in a study of 6890 adults without a history of Diabetes participating 
in the National Health and Nutrition Examination Survey (NHANES; 1999 to 
2006), the prevalence of Diabetes using A1C versus fasting plasma glucose 
criteria was 2.3 versus 3.6 percent4. Overall, the A1C and fasting plasma 
glucose criteria resulted in the same classification for 98 percent of the 
population studied. Similarly, the oral glucose tolerance test (OGTT) 
identifies different groups than an FPG level. 
In 2003, the American Diabetes Association recommended the use of 
fasting plasma glucose levels or 75g oral glucose tolerance test for 
diagnosing Diabetes7. In 2009, an International Expert Committee 
recommended using an A1C value of more than or equal to 6.5 percent to 
diagnose Diabetes8. 
THE ACTION OF THYROID HORMONE 
Thyroid hormones are major determinants of metabolic activity in 
adults, and of the development of the somatic system and the brain in 
children and infants.Thyroid hormones must be constantly available as they 
affect the function of virtually all organs / tissues / systems. For a constant 
and continuous availability, these hormones are stored in large amounts in the 
thyroid gland. Moreover, thyroid hormone secretion and biosynthesis are 
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maintained within narrow limits by a very sensitive mechanism that is 
regulated by even small changes in the concentration of the circulating 
hormones. There are two major thyroid hormones – Thyroxine (T4) and 
triiodothyronine (T3). T3 acts in virtually all tissues by altering rates of 
protein synthesis and substrate turnover primarily by modifying gene 
transcription9. Multiple factors reduce or amplify the action of thyroid 
hormones. There is an increasing recognition in the extra-nuclear 
mechanisms of thyroid hormones and these are controlled by interactions 
with components of the signal transduction system, membrane receptors, and 
the cell organelles. 
The intra nuclear mechanisms of triiodothyronine (T3) depend on four 
main factors:  
1. DNA regulatory elements  
2. The availability of the hormone 
3. Receptor cofactors 
4. Thyroid hormone nuclear receptors (TRs).  
The major regulatory element for thyroid hormone synthesis and 
secretion is the pituitary thyrotropin (TSH). Diffusion is the primary method 
by which Thyroxine (T4) and T3 in the circulation enter the cells and, in a 
few specialised tissues, such as the brain, it is by active transport. This is an 
important fact because alterations in the circulating hormone levels and 
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subsequently impaired neurologic development in boys has been attributed to 
an inherited gene defect coding for the MCT8 thyroid transporter. T4, within 
the cells, can get converted to T3, and this locally produced T3 is the one that 
majorly binds to the nuclear receptors in the majority of the tissues. This 
peripheral conversion, or in broader terms extrathyroidal conversion make up 
about eighty percent of the circulating T3 in human beings, the rest twenty 
percent is derived from direct thyroidal secretion10. 
T3 can also be regulated at the level of tissues and this is a significant 
influence on the action of thyroid hormones. The following fractions vary 
from species to species and from tissue to tissue: 1) Amount of T3 that is 
produced locally from T4; 2) The amount of locally produced T3 to the 
number of receptors that is T3 bound. In human beings, around eighty 
percent of extrathyroidal T3 formed from T4 occurs intracellularly. 
There are two Thyroid Receptors (TR) that exist, alpha and beta9. 
Separate genes encode for these two receptors which are located in 
Chromosomes seventeen and three respectively. The two receptors are 
similar structurally; but due to the mechanism of alternative splicing, each 
receptor has multiple subtypes, TR-alpha-1 and TR-alpha-2 and TR-beta-1, 
TR-beta-2, and TR-beta-3. Triiodothyronine (T3) binds to these Thyroid 
Receptors, with the exception of TR-alpha-2, and complexes are formed 
between T3 and TR, these complexes then regulate the specific genes that 
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respond to thyroid hormone by binding to regulatory proteins. If T3 does not 
bind to TR, then TR that is not complexed can cause repression of the 
expressed gene by binding to co-repressors and then to the regulatory zones 
of the genes. 
The TR subtypes contain several distinct regions that bind to DNA, T3, 
and form polymers with TR molecules, as well as other receptors which bind 
9-cis retinoic acid, such as retinoid X receptors (RXRs). The primary 
functional unit for regulation of the gene responsible for T3 hormone is a 
TR/RXR heterodimer.Thyroid hormones are themselves the predominant 
influencing factor on the activity of this particular heterodimer, but the 
influence of RXR on the nuclear receptor varies depending on its receptor 
partner. 
A large number of regulatory products interact with TRs directly. The 
5'-flanking domain (located upstream from the starting site of transcription) 
of the genes that respond to thyroid hormone containdistinct DNA sequences 
that alter expression of the gene by binding toheterodimers of TR/RXR. 
Thyroid hormone has relevant effects on development of both the 
nervous system and somatic systems, and these effects occur during both the 
embryogenic period as well as postnatally during first few years.The thyroid 
gland of the fetus starts functioning at ten to twelve weeks of gestation, and 
this is the major source of thyroid hormone in the developing fetus after the 
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first trimester, during which maternal thyroxine (T4) is the only source. In 
congenital Hypothyroidism, where the fetus cannot make any hormone, it 
receives enough T4 for normal in utero development from the mother via the 
placenta. In severe deficiency of iodine, which can be present when there is a 
deficiency of iodine or thyroid hormone in both the mother and fetus, 
development of the fetus is abnormal, and these abnormalities cannot be 
reversed with hormone replacement therapy postnatally.Pregnant females 
who are hypothyroid have a higher rate of preterm delivery and miscarriage, 
and sometimes the offspring are minimally impaired intellectually. 
Expression of the TR subtypes have similar patterns among different species 
in which it has been studied, and there is a difference in its expression in the 
tissues of the fetus and the adult.The first isoform to be expressed is TR-
alpha. Later on, TR-beta appears, and this is the time when T3 is produced 
first. Both the TR isoforms are functional, even though their discrete roles in 
the fetal development is suggested by their pattern and timing of expression. 
Triiodothyronine (T3) acts on different tissues exerting different 
actions. It is the distribution of TRs and the content of TR isoforms in various 
tissues as well as differences in the local T3 production that determine the 
variations in the actions of T311. 
There are special characteristic variations in the expression of the  
TR-alpha and TR-beta iso forms in various tissues. Kidney, Muscle, and liver 
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contain mainly TR-beta, whereas the cardiac myocytes contains similar 
amounts of TR-alpha and TR-beta. In the brain tissue, it is dominated by TR-
alpha, but some regions of the brain contains higher levels of TR-beta-2, 
especially in the pituitary and the hypothalamus, and this isoform plays a 
distinct role in negative regulation of genes by T3, such as the those for 
thyrotropin-releasing hormone (TRH) and the subunits of thyrotropin (TSH). 
Even inside a tissue (as an example, brain, heart, or bone) there is region- or 
cell-specific variation of the isoforms of TR, suggesting that the different  
TR isoforms function differently. 
Thyroid receptor gene point mutation experiments and gene knockout 
experiments performed in mice derive most of what is known about the role 
of the individual TR isoforms.The mice used in such experiments originate 
from embryonic stem cells which have mutation or deletion of the genes 
encoding TR-alpha or TR-beta and the resulting mice have the desireddefect. 
The function of the gene under study is then determined based on the 
phenotype of the mice after genetic alterationwhen compared to normal 
(wild-type) mice, as well as the influence of cofactors. TR-alpha 
deletionscausereducedgrowth and feeding, decreased bone mineralisation, 
decreased basal body temperature, and decreased heart rate. Low thyroxine 
(T4) and serum TSH are the thyroid function changes that are observed. Mice 
that are heterozygous for dominantly negative point mutations, similar to the 
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mutationsseen in TR-beta gene associated with resistance to thyroid 
hormone, have a phenotype generally similar to the TR-alpha homozygous 
deletions. Other abnormalities that are detected in mice with dominant 
negative TR-alpha mutations are nervous system developmental defects, 
impairment in adaptation to changes in temperature, and, obesity and 
impairment of lipolysis as observed in one TR-alpha mutation. Many case 
series have mentioned family members where there is resistance to thyroid 
hormone which is associated with TR-alpha gene mutations. These patients 
have low plasma T4, normal or high plasma T3, and normal to high plasma 
TSH, with signs of Hypothyroidism including abnormality in development of 
bony tissue, constipation, and decreased or altered metabolic activity. 
Inactivating the gene encoding TR-beta is linked with hyperplastic 
thyroidglands, high plasma T4 levels, and inappropriately normal plasma 
TSH levels, similar to the features of those patients with thyroid hormone 
resistance associated with a TR-beta gene mutation. Other features include 
deafness, which has a good correlation with the expression of TR-beta in the 
cochlea in normal developing mice, and increased heart rate. Survival is not 
impaired. Heterozygous point mutations in the TR-beta gene, similar to those 
with resistance to thyroid hormone, have a phenotype similar to mice 
homozygous for deletion of the gene encoding TR-beta.  
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Both TSH secretion in response to Hypothyroidism and suppression of 
secretion of TSH by T3 is defective in these mice. These observations 
suggest that TR-beta has a crucial part in increase of TSH independent of 
ligands, as well as in suppression of TSH mediated by T3.Mice in which 
deletions of both TR-alpha and TR-beta genes are present have significant 
hyperplastic thyroid tissue and elevated levels of plasma T4 (12 times more 
than usual), T3 (31 times more than usual), and TSH (up to 165 times more 
than usual) 12. They have poor growth, the mRNA for the growth hormone as 
well as the hormone itself is reduced in quantity in the pituitary gland, and 
they have low plasma insulin-like growth factor-1 levels. Bone development 
and mineralisation are impaired, and the epiphyseal plates are not organised 
well. Fertility is severely defective in the females. Survival decreases; about 
32 percent of the mice expire by three quarters years of age, as compared 
with nil deaths in the wild-type mice of the same age. Relevant target organs 
for thyroid hormones during stages of growth include inner ear, retina, small 
intestine, pituitary, and bone. 
Repression or activation of genes that are mediated by TRs also 
involve an interaction of other protein cofactors with TRs. These proteins, 
also labelled corepressors and coactivators, inhibit or activate interaction of 
the basal transcription mechanism with TR. Many cofactors interact with 
retinoid and steroid hormone receptors additional to TRs. Examples of 
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corepressors are NCoR (nuclear corepressor) and SMRT (silencing mediator 
of retinoid and thyroid receptors). Examples of coactivators are SRC (steroid 
receptor coactivators) and CBP (CREB [cAMP responding element-binding 
protein] binding - protein). In general, corepressors bind to TR when T3 is 
not present, repressing the expression of the target gene. When T3 binds to 
TR, this replaces the corepressor that is bound to TR and provokes binding of 
coactivator to activate the gene. The TR mutations in association with thyroid 
hormone resistance generally result in irreversible interactions with 
corepressors that do not get replaced by the addition of ligand, T3. In mouse 
models of thyroid hormone resistance with a TR-beta genetic mutation, 
crossing with a mouse expressing a mutated NCoR that does not bind to  
TR results in a partial "rescue" of the resistance phenotype. This finding 
indicates that irreversible binding of corepressor to the mutant TR is a crucial 
mechanism of the thyroid hormone resistance phenotype. 
The observations of studies in animals and humans indicate that these 
receptor coactivators and corepressors play crucial roles in hormone action 
and development. Knockout of the CBP and SRC genes is fatal in the 
neonates and the fetus. These findings indicate the significant nature of these 
cofactors for development, but do not give data on which genes are most 
affected when the cofactors are not present. An example of the role of a 
cofactor in thyroid hormone regulation is SRC. SRC gene deleted mice have 
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elevated plasma TSH and T4 levels, which rise rapidly in response to 
Hypothyroidism but do not come down as usual in response to exogenously 
administered T3. 
About 11 percent of individuals with the classical clinical features of 
thyroid hormone resistance do not have mutant TRs, and instead may have 
mutant cofactor genes. All genes that are controlled by T3 have DNA 
sequences that are distinct and interact with TR with great affinity9. Most of 
these sequences, known as thyroid hormone-response elements, consist of 
tandem arrangement of two hexamer (or octamer) motifs with a consensus 
sequence of AGGTCA to which T3-TR / retinoid X receptor (RXR) 
heteromers bind, separated by four base pairs. Response elements are present 
in the 5'-flanking regulatory zone of the DNA, but can be located throughout 
the gene including in flanking sequences and introns. The structures of 
response elements that lead to T3-dependant gene promotion have been well 
documented, and preferentially bind T3-TR/RXR heteromers. A single 
octameric sequence, TAAGGTCA, can also bind TR-TR dimers and promote 
gene regulation. Response elements that confer gene repression have been 
more difficult to detect, and few appear to bind only T3-TR monomers. It is 
possible that interaction with other transcription factors is involved in 
negative regulation. In all genes regulated by T3 via modification of 
transcription, it should be possible to detect a gene sequence that can be 
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linked to this regulation. With the availability of gene sequence data from the 
human genome project, it is plausible to detect genes regulated by T3 based 
upon inspecting the sequences. Direct methods to detect sequences that bind 
receptors exist and these have been used to detect genes regulated by related 
hormones, such as estrogen. 
Conversion of the prohormone T4 to the active hormone T3 and 
conversion of T3 to diiodothyronines is done by the deiodinases, which are 
expressed in a development - specific and tissue-specific pattern. Type 1 5'-
deiodinase (D1) is found mainly in muscle, kidneys and liver. In rats, 
circulating T3 is obtained from activity of this enzyme. D1 activity is reduced 
in Hypothyroidism. Type 2 5'-deiodinase (D2) is seen predominantly in 
cerebral cortex, pituitary and brown fat in rats. It is more widely present in 
humans, including the skeletal muscle, heart and thyroid, and is the major 
source of circulating T3 in humans. D2 activity is elevated in 
Hypothyroidism and deficiency of iodine. Type 3 5 - deiodinase (D3) inhibits 
T4 and is present in skin, skeletal muscle, developing brain and placenta.In 
terms of development, expression of this deiodinase occurs first, and its 
expression decreases as the other two deiodinases are expressed more.  
D3 activity is also crucial to regulate thyroid hormone action in development 
of the sensory system, especially of the inner ear. Type 3 deiodinase (D3) 
appears to have a critical part in the maturation and function of the thyroid 
20 
 
axis. This was demonstrated by a D3 gene deleted mouse model where 
central Hypothyroidism following neonatal thyrotoxicosis was seen. 
Thyroid hormones predominantly target are the heart, the metabolic 
regulation and the skeleton. Infants with congenital Hypothyroidism who are 
not treated have disordered and delayed epiphyseal development and have 
poor growth, as do some infants with thyroid hormone resistance13. 
Abnormalities in development of bone is also a prominent feature of thyroid 
hormone receptor TR-alpha and combined TR-alpha / beta knockout mice. 
All TR isoforms have expressions in the bone, and probablyinteract with 
other nuclear receptors including those for retinoids and Vitamin D. 
However, in the bone, relatively few genes regulated by triiodothyronine (T3) 
have been identified. Plasma levels of osteocalcin have a correlation with 
thyroid function, and levels of mRNA coding for osteocalcin in bone are 
stimulated by T3 in a domain-specific pattern, similar to those areas such as 
the pelvis that are most susceptible to osteoporosis in patients with 
hyperthyroidism. Bone loss mediated by Thyroid hormone is due to enhanced 
catecholamine activity due to TR-alpha function. 
The heart is a predominant target for thyroid hormone action14. Most 
patients with thyroid hormone resistance have tachycardia, indicating no 
cardiac resistance to T3. This observation is consistent with the fact that these 
patients have TR-beta mutations, since mice with TR-beta deletions do not 
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show cardiac resistance to T3. In contrast, mice with TR - alpha deletions 
have bradycardia. This is also consistent with the absence of tachycardia in 
patients treated with selective TR - beta agonists. Thyroid hormone is a 
regulator of rate of metabolism and is associated with body weight changes. 
Animal models have demonstrated that TR - alpha is important for thyroid 
hormone-mediated enhancement of adrenergic action. Humans with thyroid 
hormone resistance associated with TR - beta mutations and elevated thyroid 
hormone levels have increased stimulation of TR - alpha. The metabolic 
phenotype of increased - TR alpha stimulation is increased feeding and 
increased fatty acid oxidation. There is a direct connection between response 
of subcutaneous fat to stimulation by the adrenergic system and the thyroid 
status. The regulation of glucose uptake is more complex, but thyroid 
hormone promotes glucose uptake and polymorphisms in the D2 gene have 
been associated with glucose intolerance. Impairment of mitochondrial 
oxidative metabolism, as is seen in type 2 diabetes and the metabolic 
syndrome, may be linked to some individuals to reduced thyroid hormone 
action. Thyroid hormone also regulates metabolism by interaction with other 
metabolic nuclear receptors such asliver X receptor (LXR) and peroxisome 
proliferator - activated receptor (PPAR)-alpha. 
Many drugs have been reported that can alter thyroxine (T4) 
absorption and metabolism14. Agonists for retinoic acid receptor (RAR) and 
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retinoid X receptor (RXR), retinoids and rexinoids, suppress thyrotropin 
(TSH) and can produce central Hypothyroidism in some patients. Agents that 
have been shown to interfere with thyroid hormone action include smoking 
cigarettes, and a range of environmental agents, especially polychlorinated 
biphenyls (PCBs). It is the sodium – iodide symporter, abbreviated as NIS, 
which concentrates iodine in the thyroid gland. Agents that block NIS and 
iodine concentration include perchlorate, a water and food contaminating 
agent in some areas, and thiocyanate, an agent that is a component of 
cigarette smoke, and is also found in polluted water. Although soy is also 
estimated to be a blocker of NIS, there is no evidence that is convincing 
enough to prove that isoflavones have an in vivo inhibition of the action of 
thyroid hormones. The protein, however, can inhibit the intestinal absorption 
of T4, this step being a crucial one in children less than 1 year with 
congenital Hypothyroidism who are receiving some sort of soy-based feeds 
and taking replacement therapy for thyroid hormones orally. 
T3 and T4 act on virtually all organs and tissues in the body. They act 
on the following processes: 
Effects on the cardiovascular system – there is a direct 
catecholaminomimetic action of thyroid hormones on the heart, which leads 
to an increase in the cardiac output. This in turn rises the heart rate and pulse 
pressure. Moreover there is a cutaneous vasodilation due to the decreased 
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peripheral resistance which activates heat dissipating mechanisms and leads 
to a slight increase in body temperature. All these actions ultimately lead to a 
decreased circulation time. These actions are not due to T3 from myocytes as 
T3 is not produced from T4 in these cells, but it is the circulating T3 that 
enters the myocytes that is the cause of its action. These circulating hormones 
enter the muscle cells, combines with thyroid hormone receptors and then 
enters the nucleus. In the nucleus it promotes or inhibits the expression of 
genes. The genes that are inhibited include those for Sodium-calcium 
exchanger, beta-myosin heavy chain, T3 nuclear receptors, and 
phospholamban. The genes that are promoted include Potassium channels, 
alpha-myosin heavy chain, sodium-potassium ATPase, sarcoplasmic 
reticulum Calcium ATPase and G proteins. However, the overall result is an 
increase in the force of contraction and heart rate. There are two myosin 
heavy chain isoforms in the heart, the beta - MHC and the alpha - MHC. 
These isoforms are coded by two genes that are highly homogenous and are 
located on the short arm of chromosome 17. There are two pairs of light 
chains and two pairs of heavy chains in each myosin molecule. In the myosin 
containing beta-MHC, there is less of ATPase activity compared to the 
myosin containing alpha - MHC. The alpha - MHC is the predominant 
isoform in the atria of adults and this increases the speed of contraction. Its 
levels are increased by therapy with thyroid hormones. On the other hand, 
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their expression is depressed in Hypothyroidism, whereas that of beta-MHC 
is enhanced. 
Effects on the Nervous system – the thyroid hormones cause general 
activation of the nervous system. The cerebrospinal fluid of hypothyroid 
patients show an elevated protein level, moreover they have a slow 
mentation. On administering thyroid hormones in such patients, these 
changes are reversed. However, the oxygen and glucose consumption as well 
as the cerebral blood flow are normal in adult hyperthyroidism and 
Hypothyroidism. Thyroid hormones, in the central nervous system, are found 
in numerous locations of the gray matter. The astrocytes in the central 
nervous system are responsible for the peripheral conversion of T4 to T3, and 
it is observed that a sharp rise in the brain dopaminergic (D2) activity occurs 
after thyroidectomy, this is rapidly reversed after a single intravenous dose of 
T3 within 4 hours. There is a catecholamine stimulant activity which causes 
activation of the reticular activating system. Thyroid hormones also 
prominently affects the development of the brain, especially of the basal 
ganglia and the cerebral cortex. Thyroid hormones also affect the cochlea. 
Subsequently, deficiency of thyroid hormone during the growing phase in a 
child would lead to deaf-mutism, mental retardation and motor rigidity. The 
effects of thyroid hormones on reflexes are complex. In hyperthyroidism, the 
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stretch reflex reaction time is shortened, while the converse happens in 
Hypothyroidism.  
The actions of catecholamines and the thyroid hormones are closely 
related. The toxicity of these catecholamines is increased in rats treated with 
T4. In hyperthyroidism, certain affects like tremors, cardiovascular effects, 
and sweating can be reduced by sympathectomy or drugs like propranolol. 
Beta blockers are also used in the treatment of thyroid storm.  
Effects on skeletal muscle  – In hyperthyroidism, an entity called 
thyrotoxic myopathy occurs, which leads to muscle weakness. This is in part 
due to increased protein catabolism. Like in the myocytes, thyroid hormones 
play acrucial role in expression of genesof certain proteins, for example, the 
myosin heavy chain. Hypothyroidism may also be associated with muscle 
weakness, stiffness and cramps. 
Carbohydrate metabolism – thyroid hormones promote metabolism 
of carbohydrates in the body by stimulating oxidative phosphorylation and 
the tricarboxylic acid cycle. However, their more pronounced effect is in the 
gut where it stimulates carbohydrate absorption. This action is also 
independent of its calorigenic action.  
Effects on cholesterol metabolism – thyroid hormones cause a 
decrease in the serum cholesterol levels. This drop in the plasma cholesterol 
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is known to occur even before the rise of the metabolic rate. There is an 
increase in the number of receptors for low density lipoprotein in the liver, 
which leads to an increased clearance of the circulating cholesterol by the 
liver. This action of the thyroid hormone, however, is independent of its 
oxygen consumption stimulatory action.  
Effects on growth – for normal growth and skeletal maturation, 
thyroid hormones are an essential requirement. Bone growth is delayed and 
epiphyseal closure is slowed in hypothyroid children. Secretion of growth 
hormone is also depressed in these patients, which further worsens the effects 
of Hypothyroidism. 
SUBCLINICAL HYPOTHYROIDISM 
Subclinical hypothyroidism (SCHT) is only a biochemical definition 
and not a clinical one. The term itself implies that the patient does not have 
any overt specific symptoms characteristic of Hypothyroidism. 
Biochemically, it is defined as an elevated serum thyrotropin in the presence 
of a normal serum free thyroxine (free T4). A few patients with SCHT do 
present with certain subtle symptoms of Hypothyroidism, but there is no 
definite clinical criteria and efforts to clinically diagnose patients with SCHT 
has been in vain16, 17. Thus, SCHT is a laboratory diagnosis, not a clinical 
one.  
 In the presence of a low serum free T4 and an elevated serum TSH 
level, one can put a diagnosis of overt 
Hypothyroidism, is also defined based on laboratory values although almost 
all patients present with obvious clinical signs and symptoms of the disease.
In studies based on the general population
SCHT is from 3 to 16 percent
National Health and Examination 
individuals were diagnosed to haveSCHT
who were previously diagnosed to have 
undergoing treatment for the same. The 
in the age. The disease was also more prevalent in females when compared to 
males and was more in the whites when compared to blacks. 
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was that the prevalence strongly correlated with the upper level of normal 
TSH values.  
Subclinical Hypothyroidism in Europe was area - dependant. This 
could be explained by the fact that there were many regions of iodine 
deficiency in the country, and there was a gross variability in the intake of 
iodine. In a report, the prevalence of SCHTwas ranging from 23.9 % in 
regions deficient in iodine to 4.3% in one region having an abundance in 
iodine intake, in spite of a similarity in the prevalence of individuals with an 
elevated serum concentrations of antibodies to thyroid peroxidase  
(anti-TPO) 24. 
In the Indian subcontinent, the prevalence of Subclinical 
Hypothyroidism has been evaluated in India, Pakistan and Bangladesh. In a 
Municipal Hospital in Mumbai, 237 subjects from paramedical personnel 
registry were selected for a cross sectional observational study with an aim of 
defining the normal ranges for thyroid hormones and thyrotropin, and to 
study the prevalence of SCHT in paramedical population in Mumbai25. The 
study found a prevalence of SCHT in 11.3% cases, with a female: male ratio 
of 4: 1. Other studies in India include that by Dr Meena Desai et al. on first 
degree relatives of children with thyroiditis, Unnikrishnan et al. on 971 adults 
In cochin26, and Abraham et al. on prevalence in females in Puducherry27, all 
of them had Subclinical Hypothyroidism being the most common thyroid 
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disorder and there was a higher prevalence of the disease in females. JM 
Alam et al. assessed 230 patients (98 males, 132 females) in a general 
hospital in Karachi, in the age groups of 19 to 66 years, and found an 
increased prevalence of Subclinical Hypothyroidism(13.7%)compared to 
subclinical hyperthyroidism (7.57%) and an increased prevalence in the age 
groups 31 to 66 years and in females (Female : Male = 2 : 1)28. The higher 
prevalence of the disease compared to NHANES is probably due to the 
increased rate of endemic goitre in these regions and the pure lack of 
awareness of the disease and its preventive methods. 
ETIOLOGY OF SUBCLINICAL HYPOTHYROIDISM 
Overt Hypothyroidism and SCHT have exactly the same etiology and 
they include  
Chronic autoimmune thyroiditis 
Persistent TSH increase in subacute thyroiditis 
Postpartum thyroiditis 
Painless thyroiditis 
After thyroidectomy / radioactive iodinetherapy / external radiotherapy 
of head and neck 
Drug induced Hypothyroidism 
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Inadequate replacement therapy for overt Hypothyroidism 
Thyroid infiltration disorders  
Amyloidosis 
Sarcoidosis 
Hemochromatosis 
Riedel’s thyroiditis 
Cystinosis 
AIDS 
Primary thyroid lymphoma 
Toxic substances. 
Majority of the patients suffer from chronic autoimmune thyroiditis, 
also called Hashimoto’s thyroiditis, with elevated serum concentrations of 
antibodies to the enzyme thyroid peroxidase29. Other major causes include 
prior ablative or antithyroid drug therapy for hyperthyroidism. Drugs causing 
Hypothyroidism include amiodarone, radiographic contrast agents, lithium, 
interferonalpha, aminoglutetimide, ethionamide, sulphonamides, and 
sulfonylureas. 
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DIAGNOSIS OF SUBCLINICAL HYPOTHYROIDISM 
Subclinical Hypothyroidism is only based on laboratory testing and 
there is no clinical criteria or diagnosis for SCHT. Subclinical 
Hypothyroidism may occur in the absence or presence of clinical features of 
Hypothyroidism. Most patients are asymptomatic witha low level of serum 
TSH (<10mU/L) 30. 
Most of the institutes in the world use serum TSH as a valid screening 
test for thyroid disorder. An elevation in the serum TSH concentration should 
probe the clinician to repeat the serum TSH concentration along with a serum 
free thyroxine (serum FT4) to diagnose SCHT.The serum TSH should also be 
repeated again after 1 to 3 months for confirmation of the diagnosis and to 
rule out transient temporary elevations. In certain conditions like infertility or 
pregnancy, or conditions where there can be a strong reason to start 
treatment, one may start the patient on T4 replacement therapy if the repeat 
TSH that is done along with T4 remains increased.  
For pregnant women, elevations in TSH should be defined using 
trimester-specific TSH reference ranges. For nonpregnant adults, a high 
serum TSH is by definition, a TSH concentration above 4 to 5 mU/L, the 
upper limit of normal reference range that is considered in most reference 
laboratories. There is a lot of controversy on the ranges of TSH level. Some 
experts have mentioned that only 2.5 or 3 mU/L in healthy individuals 
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without thyroid disease should be considered as the true upper limit, while 
others are of the opinion that the serum TSH distribution changesto an upper 
level as the age advances, independent of the presence or absence of 
antithyroid antibodies31.  
Sometimes patients may have an elevated TSH values in spite of a 
completely normal thyroid gland. Some of the important explanations are: 
1. During recovery from a critical illness that is not related to the 
thyroid, where a period of suppression of TSH is followed by a 
transient increase in serum TSH. 
2. After a hyperthyroid phase of any form of thyroiditis – postpartum 
or subacute. 
3. Variability in the assays 
4. Heterophilic antibodies32 
5. Rheumatoid factor positivity32 
6. Autoantibodies to TSH which create macro-TSH33 
7. Untreated adrenal insufficiency 
8. TSH producing pituitary adenomas 
9. Central Hypothyroidism 
A Heterophilic antibody maybe interfering with immunometric assays 
used to measure the thyroid hormones32. These cause a falsely elevated 
reading in TSH value. Rarely, Heterophilic antibodies block binding of one 
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of the mouse monoclonal antibodies to TSH and result in spuriously low 
readings for TSH. Non-linearity with dilution suggests interference. Addition 
of nonimmune homologous mouse immunoglobulins has reduced this type of 
assay interference. Commercial assays exist for detecting human anti-mouse 
antibodies. Macro - TSH are antigen antibody complexes that are formed by 
the reaction with TSH and anti-TSH antibodies. These complexes are of the 
IgG type, and they lack the biologic activity of TSH, but they can still react 
with immunometric assays, causing an elevation in the TSH, even in 
euthyroid individuals33. Anti-TSH antibodies can be detected by removal of 
the IgG-TSH complexes with polyethylene glycol or protein A or G, then 
repeating the assay on the immunsubtracted sera. In patients with resistance 
to the actions of thyroid hormone, or in adenomas of the pituitary gland that 
secrete TSH, an elevation in TSH has been shown to have an association with 
an elevation in serum Free T3 and/or T4 concentrations. In contrast, patients 
with SCHT have normal free T4 levels.  
Secondary to an alteration in TSH receptor, the patient’s thyroid gland 
can develop resistance to TSH – these patients a high serum TSH 
concentration with low free T3 or T4. In Central Hypothyroidism, twenty five 
percent of the enrolled individuals have anelevated serum TSH (upto about 
10 mU/L) and a low Free T4. 
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CONSEQUENCES OF SUBCLINICAL HYPOTHYROIDISM 
A good number of patients with SCHT subsequently progress to overt 
clinical hypothyroidism. Following nearly ten to twenty years of follow - up 
in studies, new onset overt Hypothyroidism occurs in approximately 32 to 54 
percent34-36. This risk of development of clinical Hypothyroidism is related to 
the concentration of serum thyrotropin at the beginning of most studies, the 
risk being higher in the presence of antibodies to thyroid peroxidase  
(anti-TPO) and with TSH values above 12 mU/L. In one study, 1710 
individuals were studied for 21 years, and females who had  both the 
presence of antibodies against thyroid peroxidase and a high initial TSH 
value progressed to clinical Hypothyroidism at 4.2% every year28. A study 
that involved 83 women were followed up for 9.1 years, and the total 
percentage of patients who progressed to overt Hypothyroidism was one% 
for individuals with a TSH concentrations at the beginning of study being 
less than 4 to 6 mU/L34.  
Another factor that determines the risk of progression to OHT is the 
underlying thyroid disease36. Those individuals who have received either an 
external high-dose radiotherapy or therapy with radioiodine, and those 
patients with an underlying autoimmune disease are the ones at highest risk 
to progress to OHT. On the other hand, Subclinical Hypothyroidism will 
most likely be expected to persist in patients who had been exposed to 
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external radiotherapy during childhood, and in individuals after thyroid 
surgery, where the surgery has been performed for an indication other than 
hyperthyroidism. 
Some patients with SCHT spontaneously recover, but the frequency at 
which this occurs is not known34. In an observation of 422, 242 persons 
without known thyroid disease, serum TSH was elevated (5.5 to ≤10 mU/L) 
in 3 percent37. During the five-year follow-up period, TSH levels became 
normal in the absence of treatment in 62 percent of patients. Return of serum 
TSH concentrations to normal levels is expected within the 1st 2 years after 
the diagnosis of SCHT, if serum TSH levels <8mU/I, and if individuals are 
tested negative for Anti-TPO antibodies. 
Overt Hypothyroidism may be associated with an increased risk of 
cardiovascular disease (CVD). In patients with Subclinical Hypothyroidism, 
the information is controversial, mostly due to variations in sample size and 
structure and the type of study. Some38, 39, but not all40, descriptive studies 
have reported a higher chance of cardiac disease in patients with SCHT. A 
meta-analysis of information obtained from six observational studies (25,976 
enrolments, 2021 with SCHT) shows a characteristic trend of higher risk of 
fatal and nonfatal cardiac events (non fatal myocardial infarction, death due 
to cardiac disease, hospitalisation for angina or coronary revascularisation) at 
a higher concentration of serum thyrotropin41. Participants with serum 
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thyrotropin levels more than or equal to 8 mU/L had a higher rate of cardiac 
event when compared to individuals with a euthyroid status (38.5 versus 20.4 
event / 1000 person years, hazard ratio 1.88, 95% confidence interval  
1.29-2.81). On the other hand, mild increase in thyrotropin (4.6 to 6.8 mU/L) 
did not have an increased risk (HR 1.10, 95% CI 0.95-1.42). The estimation 
of risk had no variations based on presence of pre-existing cardiac disease, 
gender or age. 
In another meta-analysis from seven observational cohort reports 
(25,380 individuals, 2069 with SCHT), analysing the data revealed that there 
was a significantly higher risk of developing cardiac failure with increased 
TSH concentrations42. Comparing to patients with normal thyroid status, 
individuals with a thyrotropin level between 11 and 20 mU/L had 
significantly higher rate of developing heart failure (41 events in 225 
participants (18.2%) against 1763 patients in 22,673 controls (7.9%), HR 
1.85, 95% CI 1.26-2.73. The higher incidence of heart failure in those with a 
serum thyrotropin between 6.9 and 9.8 mU/L was not significant statistically 
(55patients in 423individuals [12.9 %], and mild thyrotropin rise (4.6 to 6.8 
mU/L) did not have any significant rise in risk. 
Some, but not all, studies show a link between thyroid dysfunction and 
lipid profile, especially the LDL and total cholesterol concentrations. In a 
large prospective study (25,863individuals, mean age 55 years), individuals 
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who had a thyrotropin level between 5.0 and 9.9 mU/L had a significant 
mean cholesterol levels that were higher than individuals with a thyrotropin 
level less than 5.0 mU/L (224 against 213 mg/dL). The drawback of this 
study was, that there was no adjustment for age for the cholesterol levels. 
Moreover, whether the increased levels is clinically significant in relation to 
risk of cardiac disease or not is not known. 
In few, but not all, reports, individuals with SCHT have a higher 
chance of mortality due to any cause. In a meta-analysis of data from  
12 observational reports, the incidence of mortality due to heart disease 
increased with higher levels of thyrotropin and was higher in patients with 
thyrotropin levels more than or equal to 9 mU/L41. On the other hand, mild 
rise in thyrotropin (4.6 to 6.8 mU/L) did not have an increased incidence of 
cardiovascular events. The incidence of all-cause mortality was insignificant 
in both the groups. In one observational study that was part of the meta-
analysis, individuals in the geriatric age group (age > 80 years) who were 
suffering from SCHT and not taken treatment, and with thyrotropin levels 
between 4.7 and 9.9 mU/L, had a reduced incidence of death due to heart 
disease or other causes compared to the general population43. Similar 
observations were seen in a study from Denmark; Subclinical 
Hypothyroidism with a TSH of 5 to 10 mIU/L had a reduced incidence of 
death due to any cause. However, a prospective cohort study from the United 
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States with older individuals with untreated SCHT had neither a higher nor a 
lower rate of mortality over a mean follow - up time of five years. 
In another cross-sectional study, non-alcoholic fatty liver disease 
(NAFLD) was compared to serum TSH levels. Thirty and 36 percent of 
individuals with subclinical or overt Hypothyroidism, respectively, had 
typical ultrasonographic findings of  NAFLD (versus 20 percent of controls) 
while 20 and 26 percent of individuals with subclinical or overt 
Hypothyroidism had abnormal liver enzymes. 
Neurological and psychiatric diseases may also be associated with 
SCHT. However one study conducted in the United Kingdom on patients did 
not show any significant correlation between SCHT and psychiatric disease 
like depression or anxiety. 
Other cardiovascular risk factors and end points may also be associated 
with SCHT. This includes inflammatory markers, functioning of the 
endothelium and thickening of the intima media of the carotid.There are 
reports of patients with SCHT developing increased vascular resistance and 
diastolic dysfunction, similar to development of the same in OHT. On the 
other hand, a report showed no abnormality in the function or the mass of the 
left ventricle in elevated serum thyrotropin levels. 
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In some, but not all, studies in middle-aged adults, increasing serum 
TSH concentrations within the normal range or slightly above normal were 
associated with a modest increase in body weight. In older women  
( > 65 years), Subclinical Hypothyroidism (mean TSH 6.7 mU/L) compared 
with euthyroidism (TSH 2.2 mU/L) was associated with a slightly higher 
baseline weight (0.51 kg higher baseline weight per 1 mU/L higher TSH 
level) but not with weight change over time. There was no relationship 
between TSH and weight in older men. 
In another study, 22 out of 34 individuals (65%) with SCHT have an 
increased rate of neurological and muscular features like fatigue and cramps, 
when compared to 7 out of 45subjects with normal levels (15%). In contrast, 
a report involving 2050 patients aged above 60 years showed that functional 
mobility was worse in those with normal range of thyroid hormones than 
those with mild elevations of thyrotropin levels44. 
Executive functioning and verbal memory may also be affected in 
patients with SCHT. Correction of thyroid status with replacement therapy 
caused an improvement of these functions. More than a general slowing in 
cognition, these defects were believed to be an abnormality in the functioning 
of the hippocampus. 
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In another study of the general population, the incidence of 
Alzheimer’s disease was higher in women with SCHT. The incidence for the 
same was not significantly high in men with SCHT. 
Subclinical Hypothyroidism is associated with a higher risk of 
thrombosis of the deep veins of the legs in a pilot study. 
Another study showed dysfunctioning of the Sphincter of Oddi leading 
to a higher incidence of stones in the common bile duct in patients with 
SCHT38. 
One report studied the treatment of iron deficiency anemia on patients 
with SCHT. It was observed that the rise in Haemoglobin was more in 
patients when they were given replacement therapy for both iron and 
thyroxine than with replacement therapy with iron alone38.  
Presence of SCHT in pregnancy confers a risk, and it is observed that 
there is an increased rate of low birth weight and miscarriages of the 
offspring38.  
EFFECTS OF THYROID HORMONE REPLACEMENT 
The most important dilemma for clinicians when managing Subclinical 
Hypothyroidism is to whether to actually treat them with hormone 
replacement therapy or not.Since there is a risk of development of OHT in 
these patients, certain experts favour therapy of SCHT, especially when the 
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level of thyrotropin goes beyond 9 mU/L. In contrast, treating patients with 
mild elevations of thyrotropin is still a question of doubt, and this is stratified 
by the fact that there is no wide-scale study to prove any benefit in treating 
them. 
The studies that have observed any relation between improved 
symptoms of Hypothyroidism and T4 replacement have varying sample sizes 
and structures, and different end targets, and so they naturally have 
conflicting results. In few studies, replacement with thyroxine showed an 
improvement in symptoms of Hypothyroidism and cognition, especially in 
patients with an initial serum thyrotropin level more than 10 mU/L. A meta-
analysis of 13 observational studies (ten studies used patients with 
thyrotropin levels less than 14 mU/L), showed no difference in the symptoms 
and signs of Hypothyroidism nor any differences in adverse effects and 
quality of life between cases and controls44. 
Other following randomized controlled studies that were not part of the 
meta-analysis mentioned above evaluated the consequences of thyroxine 
replacement therapy on symptoms of Hypothyroidism and cognition, and 
these did not show any benefit on treatment. In a double blind study, 200 
patients with serum thyrotropinaround 3.6to15.7 mU/L were treated with 100 
micrograms of T4 per day. The results showed a lower incidence of fatigue 
(90% reduction), but other symptoms as well as quality of life did not have 
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any improvements.Some patients even developed thyrotropin levels less than 
normal levels after therapy. 
The effect of Thyroxine replacement therapy on cognition was 
evaluated in one randomised control study. 95 patients more than or equal to 
65 years with a serum thyrotropin level more than 5.4 mU/L were observed 
and a mini mental status score was used to analyse cognition after 6 to  
12 months of therapy. Eighty four percent patients achieved normalization of 
thyroid function after a year of therapy.In the study, however, cognition did 
not improve significantly even after hormone replacement for 1 year. The 
trial had many limitations. There was a high rate of drop outs, and fifty 
percent individuals in the placebo group spontaneously recovered. Despite 
these limitations, the results of the meta-analysis and subsequent trials, in 
which most patients had TSH <10 mU/L, suggest that treatment of SCHT 
with thyroxine does not result in clinically significant improvement in quality 
of life, depression, and cognition. 
In patients with SCHT and goitre, T4 treatment may decrease the size 
of the goitre. As an example, in a study of 13 patients with Subclinical 
Hypothyroidism, therapy with T4 had a significant reduction (median 80 
percent) in thyroid volume determined by ultrasound. 
Although T4 replacement has been shown to correct a lot of risk 
factors for cardiac disease and endpoints in cardiovascular disease in patients 
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with Subclinical Hypothyroidism, including endothelial function, carotid 
intima media thickness, dyslipidemia, markers of inflammation, vascular 
smooth muscle proliferation, vascular reactivity, and ventricular function, 
there is limited date regarding the relation between thyroxine therapy and 
reduction in adverse cardiac outcomes. In astudy by the United Kingdom 
General Practitioner Research Database, ischemic heart disease events were 
uncommon among those patients aged 41 to 69 years treated with 
levothyroxine (69 events in 1635 treated patients [4.3%] against 96 events in 
1458 untreated patients [6.7%], hazard ratio [HR] 0.62 [95% CI 0.38-0.94]). 
However, in individuals over age 69 years there wasn’t any benefit intherapy 
(103 events in 818 treated individuals [12.8%] against 89 events in 824 
untreated patients [10.8%], HR 0.98). The incidence of adverse 
cardiovascular outcomes associated with overtreatment after thyroxine is 
administered, especially in elder individuals, is not known. Thus, more 
clinical trials need to be conducted to analyse whether thyroxine replacement 
therapy reduces adverse cardiac outcomes in patients with SCHT. 
In the meta-analysis of 11 clinical trials (eighttrials with thyrotropin 
levels less than 15 mU/L) described above, six of the trials analysed lipid 
levels after therapy of SCHT with levothyroxine. There were no significant 
effects of T4 replacement on total cholesterol, triglycerides,apolipoprotein A 
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and B, lipoprotein (a), low-density lipoprotein (LDL)cholesterol, or high-
density lipoprotein (HDL)cholesterol. 
In many studies on individuals with SCHT given thyroxine therapy 
compared with placebo, there was a significant reduction in serum apoprotein 
B-100 and total and LDL cholesterol levels. In contrast, there was no 
differences in the levels in serum lipoprotein (a), triglycerides and HDL 
cholesterol levels. All these studies included individuals with serum 
thyrotropin levels > 10 mU/L. 
THYROID DISEASE AND DIABETES MELLITUS 
The prevalence of thyroid disorders is more in patients with Diabetes 
than in those without, and more so in type 1 Diabetes than in type 2 Diabetes 
mellitus45. In the Diabetes Control and Complications trial, 58 patients having 
type 1 Diabetes mellitus, out of which were 33 women and 27 men, were 
enlisted at University of Tennessee Health Centre. These patients were 
subjected to thyroid function tests once yearly and Anti-TPO antibodies 
every four years and were followed up for a period of 18 years. It was found 
that 18 patients had Hypothyroidism, which was more in females (41%) than 
males (19%) 46. The risk of developing hypothyroidism was more in those 
with positive anti - TPO antibodies, thereby indicating that thyroid 
dysfunction in such patients have an autoimmune etiology. This validated the 
use of TPO antibodies as a screening test to predict the occurrence of 
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Hypothyroidism in type 1 Diabetes, with a positive predictive value of 67%. 
Despite this association, annual measurement of TSH still remains the best 
screening test for thyroid dysfunction. Screening for thyroid disease has been 
approved by the American college of physicians for which guidelines have 
been set by the same. Screening is not warranted for women under 50 years 
and men because of its low frequency. But since patients with type  
1 Diabetes mellitus have thyroid dysfunction at an earlier age, these 
screening tests cannot be applied if the individuals have type 1 diabetes. The 
prevalence of hyperthyroidism, however, was much lower than previously 
reported.  
The prevalence of thyroid disorders is higher in type 2 diabetes as well. 
In more than 300 patients of type 2 Diabetes, a screening test for thyroid 
dysfunction was performed, in a clinic in Segovia, Spain47. It was found that 
thyroid dysfunction was seen in 32.4% patients, out of which overt 
Hypothyroidism was the most frequent thyroid disorder with a prevalence of 
15.1%, followed by subclinical hyperthyroidism (10.7%). However, there 
was no significant correlation between thyroid dysfunction and glycemic 
profile, duration of Diabetes, and the presence of complications of Diabetes. 
The Fremantle Diabetes Study assessed thyroid function for a group of 
438females with Diabetes type 2coming under an observational study. 
Thyroid function tests, including thyroperoxidase antibodies, were measured 
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along with other parameters like HbA1C and lipid profile at baseline and 
after 5 years61. Exclusion criteria included Patients who previously had some 
form of thyroid dysfunction or is undergoing treatment for the same. The 
prevalence of SCHT was found to be 8.7%, and this prevalence was 
associated with an elevation in the antibodies to thyroid peroxidase, and age. 
However, the study could not associate Subclinical Hypothyroidism with the 
glycemic profile and lipid profile. Another fact that was observed was the 
patients who had Subclinical Hypothyroidism did not require any treatment 
and did not progress to overt hypothyroid disease after 5 years of follow up. 
Therefore, the screening of such patients for Subclinical Hypothyroidism 
remains questionable. 
One of the most popular studies in thyroid disorders and Diabetes was 
performed in Greece in 2010, where a total of 1092 type 2 Diabetes mellitus 
were enrolled. About 12.3% of diabetic patients had thyroid dysfunction, out 
of which 80% were females. Other statistically significant parameters 
included a higher body mass index, a lower HDL cholesterol and a higher 
LDL cholesterol in patients with both thyroid dysfunction and 
hyperglycemia, compared to those with only hyperglycemia without thyroid 
dysfunction. There was no correlation between presence of thyroid 
dysfunction and Duration of Diabetes, blood pressure, glycemic control 
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(HbA1C), triglyceride levels, hypertension, and complications of Diabetes 
like retinopathy, nephropathy, and coronary artery disease. 
There are very few studies that have compared the incidence of SCHT 
in the Indian subcontinent. The most significant was one trial performed in 
Bangladesh, who gathered one hundred and twenty individuals aged 41 – 70 
years in Dhaka62. However, in the trial the incidence was very low, with only 
2 individuals (3.33 percent) in the type 2 Diabetes group having Subclinical 
Hypothyroidism. Another case control study was performed by Sekar et al in 
North India, consisting of hundred cases and fifty controls, found the 
incidence of SCHT in type 2 Diabetes as 9 percent. 
OTHER COMORBID CONDITIONS IN DIABETES 
The Medical Expenditure Panel Survey is a group of surveys 
conducted on a large scale basis in families and employers in the United 
States. According to this survey, it is estimated that most adults suffer from 
one chronic comorbid condition (CCC) at the least, and around 40% 
individuals with Diabetes have three CCCs. These patients are defined 
patients with multimorbidity disease. The reason behind this is partly because 
of the improved quality in therapeutics and care provided to a diabetic, most 
notably improvements in HbA1C monitoring and glycaemic control. 
Cardiovascular deaths are in the decline because of more efficient use of 
medications like aspirin and angiotensin converting enzyme inhibitors. Due 
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to the extended longevity of diabetics, they are naturally more prone for more 
CCCs. Another important factor is the reduced patient provider visit time in 
the current era, considering the overwhelming number of health maintenance 
activities recommended by quality monitoring agencies, thereby leading to an 
inadequacy in health system support and a reduced experience in 
management of multimorbid patients by health care providers. 
Moreover, the patients’ ability in self-care management are profoundly 
affected by these comorbidities. As an example, depression and arthritis 
impairs the proper functioning of a patient and poses an enormous barrier to 
adherence to the prescribed regimen and changes in lifestyle. Certain CCCs 
can have a devastating effect on the patient’s health status rather than the 
patient’s diabetic status per se. Conditions like advanced heart failure make 
the attainment of the goals of Diabetes a Herculean task. 
Chronic comorbid conditions increase the financial burden of an 
individual in terms of medications, investigations, and inpatient expenditure. 
The following are the definitions for chronic comorbid conditions 
Clinically Dominant conditions 
Chronic comorbid conditions that are so serous / complex they mask  
the long term and short term management of other health problems.  
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• Recently diagnosed 
o Rheumatoid arthritis 
o Breast Cancer 
• Severely symptomatic 
o Severe depression 
o Class IV chronic heart failure 
• End-stage disease 
o Severe cognitive impairment or dementia 
o End stage renal disease 
Asymptomatic versus symptomatic conditions 
Treating of asymptomatic chronic conditions focus on prevention of 
early mortality and downstream adverse event exclusively 
Treatment of symptomatic chronic conditions will be focused over 
delaying or preventing poor long term outcomes, and improving functioning 
and quality of life, and the patient’s symptom profile.  
• Asymptomatic 
o Hypertension 
o Moderate to poor glycaemic control 
o Hyperlipidemia 
 
50 
 
• Symptomatic 
o Depression 
o Angina 
o Gastroesophageal reflux disease 
o Rheumatoid arthritis 
Discordant versus concordant conditions 
Discordant conditions are those that are not related to Diabetes, in 
terms of management as well as in pathogenesis. Concordant conditions are 
more likely to be part of the spectrum of disease with the same overall 
pathophysiology and risk profile with probable improvement with treatment 
plan of the original disease. 
• Discordance with diabetes 
o Chronic low backpain 
o Asthma 
o Prostatecancer 
• Concordant with Diabetes 
o Coronary artery disease 
o Cerebrovascular disease 
o Hypertension. 
o Peripheral vascular disease. 
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Some conditions, even though vigilant Diabetes care is an essential 
part of management, are considered dominant by the health care providers. In 
a study of patients who are seropositive for human immunodeficiency virus 
(HIV), it was found that, the predominant reason for admission into the 
hospital was for exclusively non-HIV related conditions (72%). In such 
patients, where both diabetes and the seropositive status are health hazards, 
some physicians may place HIV above Diabetes as the dominant disease. 
DIABETIC DYSLIPIDEMIA 
Majority of the patients with type 2 Diabetes have some alteration in 
their lipid profile at some point in their life.The characteristic dyslipidemia 
pattern that accompanies hyperinsulinemia and insulin resistance is an 
elevation in the serum triglyceride levels and a reduction in the HDL -
cholesterol levels, popularly known as diabetic dyslipidemia.The 
abnormalities in the lipid levels correlates with the insulin resistance severity. 
One trial detected insulin sensitivity using a euglycemic clamp in patients 
with and without type 2 Diabetes Mellitus found that there was an association 
between larger VLDL cholesterol particle size, smaller LDL cholesterol and 
HDL cholesterol and the resistance of peripheral tissues to insulin. There was 
also an increase in the concentrations of IDL, LDL and VLDL cholesterol 
with a consequent decrease in the concentrations of HDL cholesterol in these 
patients. 
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Kinetic studies in vitro have proved that there is a uniformly increased 
rate of secretion of VLDL, the major triglyceride-rich lipoprotein, in patients 
with type 2 Diabetes mellitus and hyperinsulinemia48. It has been shown in 
studies that lipoproteins that contain apoprotein B in their core are assembled 
and secreted in higher amounts after an increase in the influx of fatty acids 
into the liver in individuals with resistance to insulin. Increased secretion of 
apoprotein B containing lipoproteins also stimulates secretion of VLDL 
particles into the blood. VLDL, under the influence of cholesteryl ester 
transferring protein, then increases the rate of exchange of its triglycerides 
with cholesteryl ester that is present in HDL cholesterol, leading to the 
generation of HDL cholesterol particles that are rich in triglycerides. This 
TG-rich HDL acts as a substrate for the lipases either in the liver or in the 
capillary endothelium. The resultant smaller particles that are obtained after 
HDL triglyceride hydrolyzation will affect binding of ApooA1 to HDL. 
Using these assumptions, the conclusion of this study was that abnormalities 
in the lipid profiles in these individuals are mainly due to an increase in the 
transport of fatty acid into blood. 
Therefore, two factors contribute to an increase in the triglyceride 
levels – 1) a decrease in the lipolysis of TG in VLDL cholesterol, and 2) an 
increase in the substrates available for lipoprotein metabolism, namely free 
fatty acids and glucose. For counteracting these disturbances Nicotinic acid is 
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a good therapeutic option, although the correction is only partial, and the fact 
that it is a double edged sword as it can increase the resistance to insulin and 
lead to a worsening of hyperglycemia has led to a reduction in its usage and 
popularity. For example, administering this drug in one of the trials led to a 
rise in haemoglobin A1C by 22%. 
The prevalence for elevated LDL cholesterol was found to be similar in 
diabetic and non-diabetic patients of the Framingham study. This observation 
was further substantiated by the United Kingdom Prospective Diabetes Study 
(UK.PDS) where the levels of total cholesterol in diabetics wasn’t varying 
compared to non-Diabetes, and LDL cholesterol level were more elevated in 
females but comparable in males of Diabetes type 2 on comparing with 
individuals without type 2 Diabetes. In spite of this similar prevalence of the 
level of cholesterol, individuals with type 2 diabetes are more prone for 
atherosclerotic injury. This is the result of altered glycosylation and oxidation 
of LDL particles in Diabetes. Therefore, even in patients who attain a level of 
LDL cholesterol below 50 mg/dL on non HDL cholesterol below 80 mg/dL, 
they have a persistent residual cardiovascular disease risk due to the 
significantly increased LDL particle number. 
This altered lipid profile in diabetic patients pose an increased risk for 
cardiovascular morbidity and mortality. In a double blind, randomised five 
year trial, 4082 males with non HDL cholesterol more than 199 mg/dL were 
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subjected to gemfibrozil therapy aimed at raising HDL cholesterol as well as 
lowering non-HDL cholesterol49. The reduction in cardiac events incidence 
was 34% in the second year of the study itself. However, there was no 
difference in the mortality rates in the two groups.  
In India, a prospective cross-sectional study was performed in a tertiary 
hospital in Gujarat43. Around 170 diabetics were enrolled in the study over a 
period of 6 months. The mean serum total cholesterol level was 190 mg/dL. 
Around 82.5% diabetic patients had dyslipidemia, most of them having a 
mixed pattern, and the prevalence was equally distributed among the urban as 
well as the rural population. The most common mixed pattern seen was a 
high LDL cholesterol with a high triglyceride level. During the enrolment 
period, most of them had an uncontrolled glycaemic profile, and the 
prevalence of dyslipidemia in the well-treated Diabetes group was 
significantly lesser. This showed that adequate glycemic control will 
eventually lead to returning of the lipid levels to normalcy. The prevalence of 
hypertriglyceridemia and high serum LDL (56 and 57% respectively) was 
much higher than that of low serum HDL cholesterol levels (35.7%). This 
study suggested that, instead of concentrating on a specific pattern of lipid 
abnormality in diabetic patients, it is better to screen the patient with a 
complete lipid profile as any combination of dyslipidemia may be seen in 
diabetics of the Indian population. Another study was done in south India on 
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820 patients with type 2 Diabetes, and dyslipidemia was prevalent in 95% 
males and 86% females. This study had a discrepancy in the pattern of 
dyslipidemia between the genders. While the male population had a 
predominant high triglycerides and low HDL cholesterol level, characteristic 
of dyslipidemia of Diabetes as mentioned in other studies, the female 
population had a higher prevalence of an elevated LDL cholesterol and low 
HDL cholesterol. 
DYSLIPIDEMIA IN HYPOTHYROIDISM 
The reason for an increased cholesterol level in thyroid hormone 
deficiency is primarily an increased LDL cholesterol accumulation because 
of a reduced number of LDL receptors on the surfaces of cells, thereby 
leading to a reduction in LDL catabolism. Another possible mechanism is a 
functional reduction in the LDL receptors, leading to an intrinsic resistance. 
Upregulation of the LDL receptor by T4 therapy varies considerably in 
patients with different polymorphisms of the LDL receptor gene. In one 
study, patients homozygous for one specific genotype (-/-) had a four-fold 
greater reduction in serum cholesterol during T4 therapy than those who were 
homozygous for a different genotype (+/+). 
 There are other 
plasma in patients with documented thyroid hormone deficiency and these 
include: 
1. A significant increase in oxidation of 
increase is proportional to concentration of serum LDL
2. Decrease in the secretion of 
3. Reduction in transfer of 
deficiency will reduce
concentrations. 
A reduction in the action of the capillary endothelial lipase (lipoprotein 
lipase) is the chief metabolic pathway
hormone deficiency.In two comparable studies, the level of triglycerides was 
increased in one study but normal in the other.
Chylomicron remnants accumulate in 
more rapidly during T4 tr
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Majority of individuals with SCHT havenormal values of serum total 
cholesterol and its fractions.Only a few studies have documented elevated 
levels of serum lipoprotein (a), triglycerides, total and LDL-cholesterol 
concentrations. The effects of thyroxine (T4) treatment on patients with 
SCHT were similar in three randomized studiesand two reviews of the 
literature: a mean reduction in serum total cholesterol of 10 to 16 mg/dL and 
in LDL cholesterolof 12 mg/dL. Effects of T4 may be more pronounced in 
those with overt hypercholesterolemia; in one study, as an example, serum 
LDL-cholesterol fell by 36 mg/dL (0.9 mmol/L, p<0.01) in such patients.The 
net effect of treating with T4 replacement on serum lipoprotein (a) levels in 
these individualsvary; in two studies, they declined by as much as 24 percent, 
but did not change in another study. 
Serum HDL-cholesterol concentrations are low to normal in 
individuals with SCHT. The response to T4 therapy has been variable, but in 
the meta-analysis the serum HDL cholesterol concentration did not increase 
significantly. 
Remnant lipoprotein concentrations (intermediate density 
lipoproteins), a predictor of coronary heart disease risk, may also be elevated 
in both overt and Subclinical Hypothyroidism with a lowering in response to 
T4 therapy. 
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Coronary heart disease may be increased among patients with 
Subclinical Hypothyroidism who have thyrotropin (TSH) values greater than 
7 to 10 mIU/L. 
In the Indian subcontinent, a case control study was done in Nepal on 
80 patients, and it was seen that the cases had a significantly higher levels of 
total cholesterol, LDL cholesterol and triglycerides with an insignificant 
change in HDL and VLDL cholesterol compared to controls. 
Singh K and colleagues performed a case control study on 100 cases of 
Subclinical Hypothyroidism. There was a significant increase in triglycerides 
and VLDL cholesterol levels compared to controls with almost similar 
abnormalities in LDL and HDL cholesterol levels51. Bandyopadhyay et al 
studied 100 patients with Subclinical Hypothyroidism aging 17-68 years and 
observed a significant elevation in total cholesterol, LDL cholesterol, and 
triglycerides, although this elevation was marked in the female population. In 
the male population there was a significant elevation only in the serum 
lipoprotein (a) levels52. Arsanna et al also conducted a case control study in 
Indian population with an aim to assess the association of lipid profile with 
Subclinical Hypothyroidism, and observed an elevated total and LDL 
cholesterol but no significant elevations in HDL cholesterol, triglycerides and 
VLDL cholesterol in the cases53. All these studies conducted in the Indian 
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population show an inconsistent pattern in the lipid profile in patients with 
Subclinical Hypothyroidism. 
HYPOTHYROIDISM AND GLYCAEMIC PROFILE 
Thyroid hormones have both promoting and inhibitory effects on 
glucose metabolism. An increased thyroid hormone level causes an increase 
in absorption of glucose from the gut, as occurs in hyperthyroidism. There is 
a resultant rise in plasma glucose level, but studies show that this rise is 
transient and causes an increase only in post prandial glucose levels. 
However, hyperthyroidism still promotes hyperglycemia, as there is an 
increased rate of degradation of insulin, which would lead to a decrease in its 
half-life. Bech et al noticed an increase in the levels of pro-insulin after a 
meal in untreated patients of Grave’s disease. Another mechanism is an 
increased level of GLUT 2 receptors in the liver causing an increased hepatic 
glucose output in hyperthyroid patients.  
In the hypothyroid patient, the increased weight gain and increase in 
the adipose tissue mass causes an elevation in insulin resistance and therefore 
a reduction in the peripheral utilization of tissues. This causes a rise in 
plasma glucose levels. However there is a compensatory decrease in the 
hepatic glucose output and so the hyperglycemia that occurs in hypothyroid 
patients does not appear to be significant. 
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The cells used in metabolic studies of thyroid hormones are the 
monocytes as these cells contain receptors for insulin that quickly respond to 
any rise and fall of insulin concentrations, and, during the presence of insulin, 
they have a rapid rate of disposal of glucose. Monocytes also express the 
glucose transporter GLUT that is usually found in adipose and muscle tissue. 
In one study, it was observed that there was an impairment in the 
translocation of GLUT 4 transporters on cell membrane54. Another possible 
pathogenic mechanism causing hyperglycemia in Hypothyroidism is due to a 
reduced blood flow in peripheral tissues. It is known that T3 and insulin have 
similar sites of action for maintaining glucose homeostasis, and both have a 
synergistic action at both molecular and cellular levels in this aspect. 
Therefore, another possible hypothesis for an increased insulin resistance 
would be that a reduction in intracellular T3 could cause an impaired glucose 
uptake stimulated by insulin. 
In one study, the level of insulin resistance was found to be the same in 
both overt as well as Subclinical Hypothyroidism55. This study questioned the 
possibility of a direct causation between the levels of thyroid hormones and 
hyperinsulinemia. However due to a higher level of insulin resistance even in 
subclinical cases of Hypothyroidism, this study warranted that a screening 
test must be applied to the general population to detect thyroid hormone 
abnormalities.  
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A study in India used Homeostatic model assessment (HOMA) to 
assess insulin resistance56. HOMA is a tool to determine insulin resistance 
and function of beta cells from C-peptide or insulin concentrations and a 
fasting glucose level, creating a mathematical model from which estimates of 
insulin sensitivity can be derived. The study was conducted on 25 female 
individuals aged 18 to 45 years each suffering from either Subclinical 
Hypothyroidism or overt Hypothyroidism without any previous known 
diseases like Diabetes, tuberculosis, liver disorders, congestive cardiac 
failure, medications that alter thyroid functions, polycystic ovarian disease, 
other systemic illnesses, chronic kidney disease, oral contraceptive or statin 
usage, who visited a tertiary care hospital in New Delhi. Pregnant females 
were also excluded from the study. Three groups of 25 each were formed – 
‘subclinical hypothyroid’, ‘controls’ and ‘overt hypothyroid’ based on 
thyroid function tests. The HOMA IR in the control group was 0.57 (mean) 
as compared to 1.7 and 3.9 in subclinical and overt Hypothyroidism groups 
respectively. A significant correlation between insulin resistance and the TSH 
level in the overt Hypothyroidism group was noted.  
Thyroid hormones may also have an influence on the metabolism of 
carbohydrates via adipokines and gut hormones. Thyroid hormone and 
adiponectin have certain similarities in properties like increased lipolysis and 
heat production58. Adiponectin interacts with gC1q receptor in thyroid 
 mitochondria and this may have an influence in the production of thyroid 
hormones. Moreover, T3 has been demonstrated to have an inhibitory effect 
in the mRNA expression of adiponectin in the white 
The levels of adiponectin in 
some studies showing normal levels of adiponect
2005) while others showing 
et al in Greece, 200659
This hormone produced in the white adipose tissue regulates body weight an
temperature. Controversial reports have been observed regarding its plasma 
levels in Hypothyroidism
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 Hypothyroidism 
hypoglycaemic attacks in a previously euthyroid patient. The decreased rate 
of hepatic glucose output production would also lead to a reduction in the 
requirement of insulin in the patient. Leong et al demonstrated this 
phenomenon in patients with Addison’s disea
thyroid dysfunction – 
thyroid hormones, the fluctuations in sugar levels decreased.
EFFECTS OF DIABETES
LEVELS 
Thyroid disease has been documented
mellitus, more significantly in those with a poor glycaemic control. In 
diabetic patients, there occurs a blunting of the nocturnal TSH peak, so the 
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TSH response to an increased hypothalamic thyrotropin releasing hormone 
(TRH) is impaired, leading ultimately to a ‘low T3 state’. This was partially 
explained by an impaired peripheral conversion of T4 to T3 in some studies. 
Consequently, an improvement in thyroid function is expected as glycaemic 
control is achieved, but this relation was not observed in a study by Coiro et 
al in type 1 Diabetes patients60. Hyperinsulinemia and insulin resistance is 
related to increased nodularity of the thyroid gland and a Grave’s 
thyrotoxicosis can ensue. Also the retinopathy in Diabetes renders the retina 
and optic nerve more susceptible to damage, so in Grave’s disease patients 
with Diabetes, a higher incidence of dysthyroid optic neuropathy has been 
observed. 
CONSEQUENCES OF SUBCLINICAL HYPOTHYROIDISM IN 
DIABETES MELLITUS 
Very few studies have been conducted in patients having both 
Subclinical Hypothyroidism and Diabetes mellitus, and the possible 
complications that could occur at a higher frequency in such individuals. 
As a fact, both the diseases are risk factors for dyslipidemia, and so the 
lipid levels are naturally expected to have a more elevated level in these 
patients. But there are conflicting reports as to the pattern of dyslipidemia. 
Diabetes typically tends to increase the triglyceride level, and lower the HDL 
cholesterol level, whereas Hypothyroidism tends to increase the LDL 
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cholesterol and triglyceride levels. In a study in Greece on diabetic patients, 
those with thyroid disorders had a better lipid profile compared with those 
without thyroid disorders57. The reason given for this improvement is that the 
patients were on thyroid hormone replacement therapy with thyroxine, which 
would improve the lipid profile status.  
Hypothyroidism may have an adverse outcome in relation to 
nephropathy, retinopathy and cardiovascular events in diabetic individuals. In 
a cross sectional study performed in Taipei, Taiwan, a greater prevalence of 
diabetic nephropathy, but not of diabetic retinopathy, was observed in type 2 
Diabetes patient with a coexisting SCHT, and a risk of cardiac and vascular 
disease was significantly more in the group with coexisting SCHT. However, 
the all-cause mortality in the two groups did not significantly differ.A 
retrospective study in 1993 – 2005 taking into account 6540 diabetics found 
that in 472 patients who were diagnosed with a raised TSH, when compared 
to 472 age and sex matched diabetics with normal TSH level, the all-cause 
mortality was less in the group with Subclinical Hypothyroidism (24.4%) 
compared to the group without (32.8%). There was also no significant 
connection between TSH level and cardiovascular mortality. This study was 
against the fact that type 2 Diabetes patients with SCHT are at increased risk 
of adverse cardiovascular events.  
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TREATMENT OF HYPOTHYROIDISM 
Treatment of hypothyroidism focuses mainly on hormone replacement 
therapy with levothyroxine. The usual dose of l-thyroxine used is 
1.5microg/kg wt. per day, which usually amounts to 100 to 150 micrograms. 
However, low doses are sufficient for many patients till the destruction of 
residual thyroid tissue. In individuals who develop hypothyroidism after 
therapy for toxic nodular goitre, the thyroid gland develops an autonomous 
function, so doses of thyroxine replacement needs to be lowered to 70 to 120 
micrograms. 
Adults below sixty years without any previous history or current 
symptoms and signs of cardiac or vascular disease need to be started on fifty 
to hundred micrograms of l-thyroxine per day. Based on plasma thyrotropin 
(TSH) levels, the dose can be heightened or tapered, the aim of therapy being 
attainment of normal baseline TSH levels, preferably to the lower half of the 
normal limits. The response to hormone replacement therapy is gradual and 
repeat measurements of TSH should be done 2 months after starting therapy 
or after altering the dose. The clinical improvement after thyroxine therapy 
are even slower to occur. Full resolution of symptoms may not occur till three 
to six months even after TSH levels are normalized. L-thyroxine dose may 
need to be adjusted and this is done either by 12.5 or 25 microgram increase 
or decrease if TSH is elevated or low respectively. There is an elevated risk 
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of reduction in density of bone and atrial fibrillation in patients with a 
decreased TSH, whatever be the etiology, including excess therapy with T4. 
The usage of liothyronine, the commercial preparation of the thyroid 
hormone T3 (triiodothyronine) has been tried along with l-thyroxine, but 
more trials are required to prove its beneficial effects. Liothyronine alone is 
not of any use, especially in management on a long term basis, since the 
small half-life makes three or four doses per day necessary, and it is also 
associated with fluctuation of T3 levels.  
After achievement of replacement and stabilisation of TSH 
concentrations, annual follow-up is suggested by measuring plasma TSH 
levels, and if the patient is able to maintain his TSH at a normal limit for 
many years, the follow-up may be extended to once every two to three years. 
It is crucial to make sure that the patient is adherent to therapy because once 
the patient improves from symptoms and signs, he/she may think of 
discontinuing therapy without consulting a specialist.  
If the dose of l-thyroxine exceeds 200 micrograms per day, elevation 
of the TSH concentration is a reliable marker of inadherence to therapy. This 
inadherence can also explain the fluctuation in the TSH concentrations, in 
spite of a stable l-thyroxine dose. Such individuals usually have a high to 
normal unbound T4 concentrations, in spite of a high TSH level. It is 
necessary to keep this in mind since such a pattern is also suggestive of 
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disorders of the pituitary gland (secondary thyroid disorders). If an individual 
misses a dose, he/she can take two doses at once the next day. This property 
is attributable to the long half-life of T4 (seven days).  
Most guidelines suggest therapy for Subclinical Hypothyroidism only 
if the plasma TSH levels exceed 10 mU/L. Transient thyrotropin elevations 
must be kept in mind and only if TSH concentrations are high even after 
three months, it is advisable to begin therapy. Therapy for individuals with 
TSH concentrations below 10mU/L remains a controversy, but as long as 
overtreatment is prevented, correction of slightly elevated thyrotropin 
concentrations is harmless, it may even be beneficial. Therefore, therapy is 
usually begun with a low dose of replacement and then slowly increased to 
attain normalisation of TSH levels. 
 
  
  
 
 
MATERIALS AND METHODS 
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MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, Rajiv 
Gandhi Government General Hospital, and Madras Medical College, 
Chennai. 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
CONSENT: 
Written informed consent obtained. 
STUDY DURATION: 
This study was conducted over a period of six months from  
March 2014 to August 2014. 
STUDY POPULATION: 
Patients attending the outpatient department of Internal Medicine and 
patients admitted under the Institute of Internal Medicine who satisfy the 
inclusion and exclusion criteria. 
SAMPLE SIZE: 
Two hundred Individuals 
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TYPE OF STUDY: 
Observational study (Prospective cum Retrospective) 
INCLUSION CRITERIA: 
• Patients aged above 40 years with a past history of type 2 Diabetes 
mellitus 
EXCLUSION CRITERIA: 
• Patients not willing to give consent 
• Patients below 40 years 
• Patients with history of a known thyroid disease 
• Patients with biochemical or clinical features of hyperthyroidism 
• Patients with a critical illness like malignancy, heart failure 
• Patients with abnormal liver or renal function 
DATA COLLECTION AND METHODS: 
Relevant history of the patient is taken as per the questionnaire and the 
patient is also subjected to clinical examination and diagnostic investigations. 
Informed as well as written consent was attained from either the eligible 
patients or their legal representatives. Cases were screened according to 
inclusion and exclusion criteria. All the cases and controls were subjected to 
clinical and laboratory investigations as per the proforma.  The age, diabetic 
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status, medication history, past and family history, were obtained by self-
report. Blood pressure measurements were made in the right upper limb in 
supine posture using a standardized digitals phygmomanometer. Patients 
were subjected to a complete General physical and systemic examination and 
special emphasis made to screen for the microvascular and macrovascular 
complications of Diabetes. A complete blood count, a liver function test, a 
renal function test, serum electrolyte panel, fasting lipid and glucose levels 
were all obtained using standard assays. The HbA1C levels were also 
obtained from the patients. Lipid profile included Total cholesterol, LDL 
cholesterol, HDL cholesterol and plasma triglycerides. Fasting thyroid profile 
including plasma free T3, free T4, and plasma TSH were obtained using 
standard assays. The data collected were entered in the proforma and 
subjected to statistical analysis.  
STATISTICAL ANALYSIS:  
Analysis was done using SPSS Version 20. Significance was assumed 
with p value of 0.05. Association between two categorical variables was 
tested using Chi square test. All p values were two tailed and significant 
when values were less than 0.05.Results of logistic regression were given ass 
Odds ratio with 95% Confidence Interval. 
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OBSERVATIONS AND ANALYSIS 
TABLE 1 –PREVALENCE OF SUBCLINICAL HYPOTHYROIDISM: 
 Frequency Percentage (%) 
Normal 168 84 
Subclinical 
Hypothyroidism 
24 12 
Overt 
Hypothyroidism 
8 4 
Total 200 100 
P value 0.025 
CHART 1 - PREVALENCE OF SUBCLINICAL HYPOTHYROIDISM 
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 TABLE 2 
Age Normal 
 
No. % 
40 – 45 29 90.6 
46 – 55 74 88.1 
56 – 65 34 68.0 
66 – 75 25 89.3 
>75 6 100 
Total 168 84 
P value 0.450 
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0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
40 - 45 
years
46 -55 
Years
91% 88%
9%
7%
0% 5%
73 
–AGE DISTRIBUTION 
Subclinical 
Hypothyroidism 
Overt 
Hypothyroidism
No. % No. % 
3 9.4 0 0 
6 7.1 4 4.8 
13 26.0 3 6 
2 7.1 1 3.6 
0 0 0 0 
24 12 8 4 
.1 – AGE DISTRIBUTION 
56 -65 
Years
66 -75 
Years
above 75 
Years
68%
89%
100%
26%
7%
0%
6% 4%
Overt Hypothyroidism
Subclinical Hypothyroidism
Normal
 
Total 
No. % 
32 100 
84 100 
50 100 
28 100 
6 100 
200  
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CHART 2.1 – AGE DISTRIBUTION OF PATIENTS WITH 
SUBCLINICAL HYPOTHYROIDISM 
 
TABLE 3 - GENDER DISTRIBUTION 
 Male Female Total 
Normal 80 (87%) 88 (81.5%) 168 (84%) 
Subclinical 
Hypothyroidism 
9 (9.8%) 15 (13.9) 24 (12%) 
Overt 
Hypothyroidism 
3 (3.3%) 5 (4.6%) 8 (4%) 
Total 92 108 200 
P value 0.045 
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 CHART 3.3 – GENDER DISTRIBUTION IN PATIENTS WHO HAD 
OVERT 
TABLE 4.1 – RELATION BETWEEN HbA1C AND TSH
TSH 
(microIU/mL) TSH 0.3 
HbA1C < 7% 
HbA1C 7 – 8% 
HbA1C 8 – 9% 
HbA1C 9 – 10% 
HbA1C > 10% 
 
P value 0.25  
Females, 5
76 
HYPOTHYROIDISM
– 5.5 TSH 5.5 – 6.5 TSH > 6.5
56 (33.3%) 0 (0%) 3 (15%)
51 (30.4) 6 (50%) 5 (25%)
34 (20.2) 1 (8.3%) 1 (5%)
9 (5.4) 1 (8.3%) 2 (10%)
18 (10.7) 4 (33.3%) 9 (45%)
168 12 20
OVERT HYPOTHYROIDISM
 
 
 Total 
 59 
 62 
 36 
 12 
 31 
 200 
Males, 3
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CHART 4.1 – RELATION BETWEEN HbA1C AND TSH 
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 CHART 4.3 – HbA1C in 
TABLE 4.2 – MEAN HbA1C IN TYPE 2 DM WITH AND 
WITHOUT 
 
Normal 
Subclinical 
Hypothyroidism 
 
 
4%
Subclinical hypothyroidism and HbA1C
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SUBCLINICAL HYPOTHYROIDISM
 
HYPOTHYROIDISM 
N Mean HbA1C 
168 7.9242 
24 8.531 
8%
42%
17%
29%
 
 
 
SD 
1.543 
1.644 
HbA1C <7
HbA1C 7-8
HbA1C 8-9
HbA1C 9-10
HbA1C >10
79 
 
TABLE 5.1 – DURATION OF DIABETES AND TSH 
TSH 
(mu/ml) 
Duration of 
Diabetes 
 
0.3 – 5 
 
5 – 5.5 
 
5.5 – 6.5 
 
>6.5 
 
Total 
<1 year 2 (1.2%) 0 2 (13.4) 0 (0) 2 
1-4 years 42 (27.3%) 6(42.9%) 3 (20%) 4 (23.5%) 55 
4-7 years 42 (27.3%) 3(21.4) 5 (33.3%) 4 (23.5%) 54 
7-10 years 21 (13.6%) 1(7.1) 2 (13.3%) 6 (35.3%) 32 
>10 years 47(30.6%) 4(28.5%) 3 (20%) 3 (17.6%) 57 
Total 154(100%) 14(100%) 15 (100%) 17 (100%) 200 
P = 0.450 
CHART 5.1 – DURATION OF DIABETES AND TSH 
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 CHART 5.2 DURATION OF 
TABLE 5.2 – MEAN DURATION OF 
AND WITHOUT 
 
Normal 
Subclinical 
Hypothyroidism 
 
 
DURATION OF DIABETES IN SUBCLINICAL 
<1 year
80 
DIABETES IN SUBCLINICAL 
HYPOTHYROIDISM 
 
DIABETES IN T2DM WITH 
SUBCLINICAL HYPOTHYROIDISM
N Mean duration 
168 7.28 years 
24 5.72 years 
9%
22%
30%
22%
17%
HYPOTHYROIDISM (%)
1-4 years 4-7 years 7-10 years >10 yers
 
 
SD 
5.37 
3.19 
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TABLE 6.1 – TOTAL CHOLESTEROL IN T2DM WITH AND 
WITHOUT THYROID DYSFUNCTION 
Total 
Cholesterol 
Normal 
Subclinical 
Hypothyroidism 
Overt 
Hypothyroidism 
Total 
<200 mg/dL 117 (69.6%) 13 (54.1%) 5 (62.5%) 135 
>200 mg/dL 51 (30.4%) 11 (45.9%) 3 (37.5%) 65 
Total 168 (110%) 24 (100%) 8 (100%) 200 
 P value 0.309 
CHART 6.1 – TOTAL CHOLESTEROL IN TYPE 2 DM WITH AND 
WITHOUT SUBCLINICAL HYPOTHYROIDISM (%) 
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TABLE 6.2 – LDL CHOLESTEROL IN TYPE 2 DM WITH AND 
WITHOUT SUBCLINICAL HYPOTHYROIDISM 
LDL 
Cholesterol 
Normal 
Subclinical 
Hypothyroidism 
Overt 
Hypothyroidism 
Total 
<100 mg/dL 79 (47%) 8 (33.3) 5 (62.5%) 95 
>100 mg/dL 89 (53%) 16 (66.7) 3 (37.5%) 105 
Total 168 (100%) 24 (100%) 8 (100%) 200 
P value 0.094 
CHART 6.2 - LDL CHOLESTEROL IN TYPE 2 DM WITH AND 
WITHOUT SUBCLINICAL HYPOTHYROIDISM 
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TABLE 6.3 – HDL CHOLESTEROL IN TYPE 2 DM WITH AND 
WITHOUT SUBCLINICAL HYPOTHYROIDISM 
HDL 
Cholesterol 
Normal 
Subclinical 
Hypothyroidism 
Overt 
Hypothyroidism 
Total 
>40 mg/dL 102 (60.7%) 12 (50%) 3 (37.5%) 117 
<40 mg/dL 66 (39.3%) 12 (50%) 5 (62.5%) 83 
Total 168 (100%) 24 (100%) 8 (100%) 200 
P value 0.632 
CHART 6.3 – HDL CHOLESTEROL IN TYPE 2 DM WITH AND 
WITHOUT SUBCLINICAL HYPOTHYROIDISM 
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TABLE 6.4 – SERUM TRIGLYCERIDE LEVELS IN TYPE 2 DM 
WITH AND WITHOUT SUBCLINICAL HYPOTHYROIDISM 
Serum 
Triglycerides 
Normal 
Subclinical 
Hypothyroidism 
Overt 
Hypothyroidism 
Total 
<100 mg/dL 79 (47%) 0 (0%) 2 (25%) 81 
100 - 149 mg/dL 66 (39.3%) 5 (20.8%) 1 (12.5%) 72 
>150 mg/dL 23 (13.7%) 19 (79.2) 5 (62.5) 47 
Total 168 (100%) 24 (100%) 8 (100%) 200 
P value 0.008 
CHART 6.4 – SERUM TRIGLYCERIDE LEVELS IN TYPE 2 DM 
WITH AND WITHOUT SUBCLINICAL HYPOTHYROIDISM 
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TABLE 6.5 – MEAN VALUES OF CHOLESTEROL LEVELS AND 
TRIGLYCERIDES IN TYPE 2 DM WITH AND WITHOUT  
THYROID DYSFUNCTION 
 
Total 
Cholesterol 
LDL-C HDL-C Triglycerides 
 Mean SD Mean SD Mean SD Mean SD 
Normal 181.9 36.16 108.39 33.9 42.44 7.5 151.3 45.17 
Subclinical 
Hypothyroidism 189.17 35.5 121.15 34.1 42.45 12.1 184.4 44.8 
Overt 
Hypothyroidism 193.2 37.3 108.9 30.7 39.3 10.6 148.3 35.1 
 
CHART 6.5 – MEAN VALUES OF CHOLESTEROL LEVELS AND 
TRIGLYCERIDES IN TYPE 2 DIABETES MELLITUS WITH AND 
WITHOUT THYROID DYSFUNCTION 
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TABLE 7 – AGE AND GENDERWISE DISTRIBUTION OF SERUM 
TRIGLYCERIDE LEVELS IN TYPE 2 DM AND  
SUBCLINICAL HYPOTHYROIDISM 
Triglycerides 
(mg/dL) 
<50 years 50 – 70 years >70 years Total 
M F M F M F  
<150 0 1 1 2 0 1 5 
150 – 200 0 5 4 0 0 0 9 
>200 0 1 4 5 0 0 10 
Total 0 
(0%) 
7 
(29.2%) 
9 
(37.5%) 
7 
(29.2%) 
0 
(0%) 
1 
(4.1%) 
24 
 
CHART 7 - AGE AND GENDERWISE DISTRIBUTION OF SERUM 
TRIGLYCERIDE LEVELS IN TYPE 2 DM AND  
SUBCLINICAL HYPOTHYROIDISM 
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TABLE 8.1 – GENDER DISTRIBUTION OF TYPE 2 DIABETES 
PATIENTS WITH AND WITHOUT DYSLIPIDEMIA 
 Normal  
lipid profile 
Dyslipidemia Total 
Males 25 (27.2%) 67 (72.8%) 92 (100%) 
Females 22 (20.4%) 86 (79.6%) 108 (100%) 
Total 47 153 200 
P value 0.924 
CHART 8.1 - GENDER DISTRIBUTION OF TYPE 2 DIABETES 
PATIENTS WITH AND WITHOUT DYSLIPIDEMIA
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TABLE 8.2 – GENDER DISTRIBUTION OF DYSLIPEDEMIA IN 
PATIENTS WITH TYPE 2 DM AND SUBCLINICAL 
HYPOTHYROIDISM 
 
Normal lipid 
profile 
Dyslipidemia Total 
Males 0 9 (100%) 9 (100%) 
Females 3 (20%) 12 (80%) 15 
Total 3 21 24 
 
CHART 8.2 – GENDER DISTRIBUTION OF DYSLIPIDEMIA IN 
PATIENTS WITH TYPE 2 DM AND SUBCLINICAL 
HYPOTHYROIDISM 
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DISCUSSION 
The study was done in two hundred patients in Rajiv Gandhi 
Government General Hospital at the Institute of Internal Medicine. Cases 
were obtained from both inpatient as well as outpatient department. Cases 
were patients who were known to have Type 2 Diabetes Mellitus for any 
duration, and aged above 40 years. Fasting thyroid function tests, Fasting 
Lipid profile and Serum Glycated Haemoglobin was taken for all patients. 
Fasting thyroid function tests included serum free T3, free T4 and serum 
thyrotropin (TSH). Fasting lipid profile included Total cholesterol, low 
density lipoprotein cholesterol (LDL-cholesterol), high density lipoprotein 
cholesterol (HDL-cholesterol) and serum triglyceride levels. Free T4 and 
serum TSH were obtained via chemiluminescence assay. Lipid profile was 
obtained via standard laboratory assays for the same. Glycated haemoglobin 
values were obtained via high performance liquid chromatography. Patients 
were also subjected to liver function tests, renal function tests, complete 
blood count and all those who had an abnormality in these tests were 
excluded. Due to lack of studies correlating thyroid function and 
microvascular complications of Diabetes, patients with overt diabetic 
neuropathy, retinopathy and nephropathy were excluded from the study. 
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Prevalence of Subclinical Hypothyroidism 
Out of 200 individuals included in the study 168 patients had normal 
thyroid function. This accounted for 86 percent of the cases. Twenty four 
individuals had a biochemical diagnosis of Subclinical Hypothyroidism. This 
accounted to about 12 %. Eight individuals had overt Hypothyroidism, 
diagnosed as an elevated thyrotropin level with a suppressed free T4 level as 
well. The p value was 0.025. The study showed a statistically significant 
incidence of Subclinical Hypothyroidism in patients with type 2 Diabetes.  
 The study showed an incidence of Subclinical Hypothyroidism that 
was similar to other studies. The study correlated best with a trial performed 
in Greece in 2010, where a prevalence of SCHT was 12.4%, as compared to 
12 % in our study61.  
 This study had a higher rate of Subclinical Hypothyroidism compared 
to few other studies. In the study in Segovia, Spain, it was 10.7%47, and in the 
Fremantle Diabetes Trial, it was 8.8%. The study however did not include 
testing the patients for Anti thyroid antibodies (Antibodies to thyroid 
peroxidase enzyme) that was done in all the studies mentioned above. 
 
 
 
91 
 
Age Distribution  
The individuals included in the study were separated based on groups 
into ages 40 – 45 years, 46 – 55 years, 56 – 65 years, 66 to 75 years and more 
than 75 years. It was observed that majority of the members included in the 
study fell into the age groups 46 to 55 years (84 out of 200, 42 percent), 
followed by 56 to 65 years (50 out of 200, 25 percent). The age group that 
had the minimum members was >75 years group, which consisted of 6 out of 
200 (3 percent). However, even though the overall individuals included in the 
study was higher in the 46 to 55 years age group, the incidence of SCHT was 
higher in the 56 to 65 years group, with 13 individuals in this group having 
SCHT (26 percent in the age group). In the 46 to 55 years age group, the 
incidence of SCHT was 6 out of 84 (7.1 percent in the age group). However, 
the stratification of the observed individuals based on age did not prove to be 
of any statistical significance (p value 0.450). The average age of individuals 
with type 2 DM and a normal thyroid function test was 55.21 years, and 
average age of those who had type 2 DM and SCHT was 55.54 years. 
The age stratification was not significant statistically in the Greece trial 
as well (p value 0.17)61. The average age of diabetic individuals with an 
abnormal thyroid function was 65.54 years, compared to 67.12 years in 
diabetic individuals with a normal thyroid function. There was also no 
significant difference in age in the Fremantle Diabetes Study as well. One 
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study that showed a statistically significant increase in the incidence of SCHT 
in Type 2 DM was by Kim et al, where the mean age of patients with a 
normal thyroid status was 57.9 years and those with SCHT was 61.8 years64. 
In Karnataka, India, a study in a medical college on hundred and 
fifteen individuals was performed and the mean age was similar to ours – 
54.83 years65. Another study in South India had a mean age of 58.77 years. 
These two studies had similar age group stratification which possibly 
indicates that the incidence of SCHT in Type 2 DM in India may occur at a 
slightly younger age. However more trials are necessary to substantiate this 
observation. 
Gender Distribution 
The participants of the study were divided based on the gender and it 
was observed that 92 individuals out of 200 were males (46 percent), and 108 
out of 200 females (54 percent). Among the male population, 80 individuals 
(87 percent males) had normal thyroid function, 9 had SCHT (9.8 percent) 
and 3 had overt HT (3.3 percent). Among the females, 88 individuals (81.5 
percent females) had normal thyroid function, 15 had SCHT (13.9 percent) 
and 5 had overt HT (4.6 percent). Among patients with SCHT, 9 of the 
individuals were males, accounting to 37.5% individuals. The rest 15 out of 
24 patients were females, making up 62.5% of the population. Among 
patients with overt Hypothyroidism, 3 out of 8 individuals were males (37.3 
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percent) and the other five are males (62.5 percent of the population). The 
incidence of SCHT in patients with type 2 DM is clearly more prominent in 
females, and this observation has been statistically significant in the study (p 
= 0.045). 
 Most of the trials conducted for similar aims have noticed an almost 
similar pattern of distribution of patients. The Fremantle Diabetes Study was 
done exclusively in females and had a lower prevalence of SCHT of about 
8.7% compared to 13.9 percent in our study69. Chen HS et al revealed in a 
study in Taiwan that SCHT was 5.3% in males and 8.4% in females with type 
2 DM68. In the Greek study, the prevalence was much higher at 18.5% in 
females, and 5.5 percent in males, the male prevalence being almost 
comparable to other studies61. 
 In the Indian population, only one significant study evaluated the 
gender distribution of Subclinical Hypothyroidism in type 2 DM, with the 
prevalence being 22 percent in females and 4 percent in males, the female 
prevalence being much higher than in the present study. 
Subclinical Hypothyroidism and glycemic profile 
 Individuals were grouped according to Glycated haemoglobin levels 
(HbA1C) into HbA1C <7%, 7 to 8 %, 8 – 9 %, 9 – 10 %, and > 10 %, and 
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normal and abnormal TSH values into 0.3 – 5.5 microIU/mL, 5.5 to 6.5 and 
>6.5 microIU/mL.  
 Most patients with a normal TSH value had an HbA1C below 8% (107 
out of 168 individuals, making up 63.7% euthyroid individuals). Only 18 out 
of 168 individuals (10.7 percent) had very high HbA1C levels more than 10% 
and yet had a normal thyroid function test. 
 Among individuals with increased TSH values, 40.63 percent of them 
had higher HbA1C more than 10 %, the prevalence in this group increasing 
as TSH increased (9 out of 20 [45 percent] in TSH > 6.5 microIU/mL group 
compared to 4 out of 12 [33.3 percent] in the group with TSH between 5.5 to 
6.5 microIU/mL). However, this was found to be statistically insignificant (p 
value 0.25).  
The mean HbA1C value in diabetic individuals without thyroid 
abnormalities was 7.93 %. The mean HbA1C value in individuals with type 2 
DM and Subclinical Hypothyroidism was 8.53 %. The mean HbA1C value in 
individuals with type 2 DM and Overt Hypothyroidism was 8.085%. The 
average HbA1C in individuals with an abnormal thyroid function was 8.31 
%, a value higher than those with normal thyroid function. 
 Most of the studies comparing Subclinical Hypothyroidism and type 2 
Diabetes could not come up with a statistically significant correlation 
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between level of thyroid dysfunction and glycemic profile. In contrast, the 
Greek study on type 2 DM patients showed a reduced HbA1C level in 
patients with coexisting Hypothyroidism (7.38% compared to 7.81%) 
although this was statistically insignificant61. The same observation was made 
by Kim et al in Taiwan, with a mean HbA1C of 8.8 and 8.4% in euthyroid 
and hypothyroid diabetic individuals respectively67. The variations in the 
above observations and the absence of any significant findings is probably 
due to the multiple mechanisms by which Hypothyroidism can decrease as 
well as increase the blood glucose values. 
Duration of Diabetes and Thyroid Dysfunction 
Participants were divided into 5 groups according to the duration of 
Diabetes from the detection to present, into less than 1 year, 1 to 4 years, 4 to 
7 years, 7 to 10 years, and more than 10 years. Participants were also grouped 
according to TSH values. It was observed that there was no significant 
correlation between thyroid dysfunction and the duration of Diabetes (p value 
0.45). Majority of the individuals had a duration of Diabetes below 7 years, 
regardless of whether their thyrotropin levels were high or not. In patients 
with TSH levels below 5.5 microIU/mL, 52 participants (30.9 percent of 
euthyroid diabetics) had duration of Diabetes more than ten years, some even 
had duration more than 20 years. On the other hand, only 6 out of 32 
individuals (18.75 percent) with a TSH level above 5.5 microIU/mL had 
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duration of Diabetes more than 10 years. In individuals with type 2 DM and 
SCHT, the duration of Diabetes was almost equally stratified, majority (30 
percent) of the cases fell into the 4 to 7 years group. 
 The mean duration of Diabetes among diabetic individuals with normal 
thyroid status was 7.28 years, the mean duration among those with SCHT 
was 5.72 years. So there is no relation between the prevalence of SCHT and 
the duration of Diabetes. This variation in the average values is possibly 
because of the wide range of values considered. The median value, however, 
in both the euthyroid group and in the group with SCHT, was 6 years. 
 In the study in Greece, the mean duration was 14.28 and 14.64 years 
among individuals with and without thyroid dysfunction respectively61. There 
was no significance in the duration of Diabetes regarding the prevalence of 
thyroid dysfunction. In India, in a study in Karnataka, the mean duration of 
Diabetes in the SCHT group was 6.15 years67. Two studies in the South East 
Asian Region had a mean duration of Diabetes of 8.9 years and 8.3 years66. 
The above difference may be due to the differences in the mean age of SCH 
patients in the studies as well – 55.54 in the present study versus 61.7 years in 
the study by Kim et al versus 61 years in the study by Yang et al66. 
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Total Cholesterol and Subclinical Hypothyroidism 
 The upper limit of normal of serum total cholesterol was taken as 200 
mg/dL as per the standards in the biochemistry department. Based on this, 
participants were separated into two groups – one with a normal (<200 
mg/dL) and abnormal (>200 mg/dL) total cholesterol. In patients with Type 2 
DM and normal thyroid, 30.4 percent (51 out of 168) had an abnormal Total 
cholesterol, whereas in patients with Subclinical Hypothyroidism 45.9 
percent (11 out of 24) had an abnormal total cholesterol. The mean values of 
total cholesterol in the euthyroid group and the SCHT group were 181.9 
mg/dl and 189.17 mg/dl respectively. Although the percentage of individuals 
with a higher cholesterol level was more in the SCHT group, the correlation 
was statistically not significant.  
 In the study in Greece, it was observed that diabetic patients with 
thyroid dysfunction had a better lipid profile61. Mean total cholesterol values 
were 199.8 and 207.24 in the groups with and without thyroid dysfunction 
respectively. Satvic et al found a higher mean total cholesterol value in 
patients with SCHT and Diabetes type 2 but could not elicit any significant 
correlation between the two. The same findings were observed in a trial by 
Kim et al67.  
 However, in a study conducted in Western Australia, patients with 
SCHT had significantly higher total cholesterol levels than euthyroid 
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individuals (mean 243.62 versus 224.28, p value <0.001)69. In a trial by Gray 
et al, it was observed that diabetic individuals with an increased TSH without 
clinical signs of thyroid failure had a significantly higher mean serum total 
cholesterol concentration (262.95 mg/dl in elevated TSH group versus 232.02 
mg/dl in normal TSH group; p value 0.025) after matching for age and sex. 
 There are studies performed to demonstrate the effect of treatment of 
SCHT with thyroid hormone replacement therapy. Ineck et al performed a 
trial in USA, and they observed that therapy with l-thyroxine reduced the 
total cholesterol levels70. In the current study, all 11 SCHT participants who 
had an elevated total cholesterol were already taking statin therapy, so it 
would be inappropriate to study the effect of replacement therapy on serum 
lipids in these patients.  
Low Density Lipoprotein (LDL) Cholesterol and Subclinical 
Hypothyroidism 
 The upper limit of normal of serum LDL cholesterol as per the 
standards in department of Biochemistry was taken as 100 mg/dL. 
Participants were grouped into those having normal and abnormal serum 
LDL cholesterol levels (<100 mg/dL and >100 mg/dL respectively). The total 
number of participants with an abnormal serum LDL cholesterol was 105 out 
of 200. Fifty three percent of individuals with normal thyroid function (89 out 
of 168) had an elevated LDL cholesterol, versus 66.7 percent in patients with 
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SCHT (16 out of 24) and 37.5 percent in those with overt Hypothyroidism (3 
out of 8). The p value was 0.094 and there was no statistical significance 
between thyroid status and LDL cholesterol. The mean LDL cholesterol 
values were 108.39 mg/dL, 121.15 mg/dL and 108.9 mg/dL in normal 
thyroid, subclinical hypothyroid, and overt hypothyroid groups respectively. 
There was a significantly higher prevalence as well as a higher average value 
in those patients with both type 2 DM and SCHT.  
 Papazafiropoulou et al found an improved LDL cholesterol profile in 
diabetic individuals with abnormal thyroid function which was statistically 
significant as well (114.94 in dysthyroid individuals versus 128.05 in 
euthyroid p value 0.001)61. Satvic et al and Kim et al found a similar LDL 
profile as compared to the present study but could not arrive at a significant 
correlation66, 67. In the Fremantle Diabetes study, a significantly higher serum 
LDL level was observed in the SCHT group than in euthyroid individuals 
(mean 166.28 versus 135.35, p value <0.001)69. Levothyroxine therapy 
reduced serum LDL cholesterol levels in a group of SCHT patients observed 
by Ineck et al70. Effects of therapy, however, was not studied in the present 
study. 
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High density lipoprotein (HDL) cholesterol and Subclinical 
Hypothyroidism 
 The normal limits of HDL cholesterol was set as more than 40 mg/dL. 
Participants were grouped into those with low and normal HDL cholesterol 
levels (less than 40 and more than 40 mg/dL respectively). The prevalence of 
patients with a low HDL cholesterol was 39.3 percent in normal thyroid 
status group (66 out of 168), 50 percent in SCHT group (12 out of 24) and 
62.5 percent in the overt Hypothyroidism cases (5 out of 8). This showed a 
rising trend in the prevalence of abnormal HDL cholesterol levels from 
normal to subclinical hypothyroid to overt hypothyroid cases. However, this 
trend was shown to be statistically insignificant (p value 0.632). The mean 
values of HDL cholesterol were 42.44, 42.45 and 39.3 in normal thyroid 
individual, individuals with SCHT and those with OHT respectively. 
 Satvic et al compared the mean values of serum HDL cholesterol in 
euthyroid and SCHT patients with Diabetes mellitus and found a lower 
average value in SCHT (38.14 versus 40.06) but was insignificant66. Similar 
observations were made by Kim et al67. The Fremantle Diabetes study on 
diabetic women showed a lower mean HDL cholesterol in the patients with 
higher serum thyrotropin levels (43.7 versus 45.24) but was found to be 
statistically insignificant69. In Greece, however, the mean HDL cholesterol 
was above normal limits in both dysthyroid and euthyroid groups, but the 
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diabetics with abnormal thyroid function had a higher HDL cholesterol (51.7 
versus 47.35) which was statistically significant61. 
Serum Triglyceride levels and Subclinical Hypothyroidism 
 The normal value of serum triglyceride levels was taken to be below 
150 mg/dL as per standard laboratory definitions. However, there is an 
increased risk of adverse cardiac and vascular outcomes with a triglyceride 
level above 100 mg/dL. So participants were divided into 3 groups - < 100 
mg/dL, 100 – 150 mg/dL and >150 mg/dL. 
 Among individuals with type 2 DM and normal thyroid status, 79 of 
them (47%) had serum triglyceride levels less than 100 mg/dl, 66(39.3 
percent) between 100 to 150 mg/dl and only 23 (13.7 percent) had an 
increased triglyceride level more than 150 mg/dl. Among those with SCHT, 
all patients had triglyceride levels above 100 mg/dl, with 5 patients having 
levels between 100 and 150 mg/dl (20.8%) and the majority, 19 members 
(79.2 percent) having elevated levels of triglycerides >150 mg/dl. In the 
members with overt Hypothyroidism, 2 (25 percent) had levels below 100 
mg/dl, and 5 (62.5 percent) had levels above 150 mg/dl. Only 1 patient had 
levels between 100 to 150 mg/dl. The observation that elevated levels of 
triglycerides are seen in the group with Subclinical Hypothyroidism was 
statistically relevant (p value 0.008). The mean values of serum triglyceride 
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levels were 151.3, 184.4 and 148.3 mg/dL in euthyroid, SCHT and Overt 
Hypothyroidism patients respectively. 
 In the Subclinical Hypothyroidism group, it was shown that majority of 
the patients with an elevated triglyceride level were females (11 out of 19, 57 
percent), and 13 out of 19 members affected (68.42 percent) were in the age 
groups 50 to 70 years. None of the members with elevated triglyceride levels 
were above 70 years of age, and an increasing trend in prevalence of 
hypertriglyceridemia with age could not be demonstrated. This may be 
because of the small sample size that was studied for lipid profiles in SCHT 
group. 
 In the trial conducted by Satvic et al, the mean triglyceride level was 
178 mg/dl in the SCHT group and 151 in the Euthyroid group, but the 
difference in the levels was statistically insignificant (p value 0.185)66. Kim 
et al found a lower mean triglyceride value (195 mg/dl in normal thyroid 
individuals versus 182 mg/dl in SCHT individuals) in SCHT patients 
compared to diabetics with normal thyroid function67. The Fremantle 
Diabetes Study and trials conducted by Papazafiropoulou et al also could not 
elicit a significant correlation between presence of SCHT and 
hypertriglyceridemia61, 69.   
 Overall, dyslipidemia (any abnormality in the serum total cholesterol, 
serum HDL cholesterol, serum LDL cholesterol and serum triglycerides) was 
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more prevalent in females than males. 153 participants had dyslipidemia 
(76.5 percent) and dyslipidemia was present in 79.6 % females (86 out of 
108) and 72.8% of males (67 out of 92). The prevalence in females, was not 
statistically significant (p value 0.924). In the patients with both type 2 DM 
and Subclinical Hypothyroidism, all the males had evidence of some form of 
dyslipidemia (9 males, 100%) and 80% females had dyslipidemia (12 out of 
15 females).  
 Several studies have demonstrated an increased prevalence of 
dyslipidemiain females with type 2 Diabetes. However, in the trial in Greece 
conducted on diabetics, dyslipidemia was more common in males than 
females, and this prevalence was more prominent in patients with coexisting 
SCHT. The observation was, however, statistically insignificant. In the study 
conducted by Satvic et al, there was a higher prevalence of dyslipidemia in 
females compared to males in both the groups, that is in patients with only 
type 2 Diabetes, and in patients with both type 2 DM and Subclinical 
Hypothyroidism. 
  
  
 
 
CONCLUSION 
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CONCLUSION 
1. There is a significant incidence of Subclinical Hypothyroidism among 
individuals having Type 2 Diabetes Mellitus.  
2. The incidence of Subclinical Hypothyroidism among individuals 
having Type 2 Diabetes Mellitus is significantly higher in females than 
males. 
3. There is no significant relationship between incidence of Subclinical 
Hypothyroidism in Type 2 Diabetes and age, and duration of Diabetes. 
4. There is no significant effect of the presence of Subclinical 
Hypothyroidism in patients with type 2 Diabetes Mellitus over HbA1C 
(Glycemic profile) 
5. There is no significant effect of the presence of Subclinical 
Hypothyroidism in patients with Type 2 Diabetes Mellitus over Total 
cholesterol, LDL cholesterol, and HDL cholesterol levels. 
6. Patients with Type 2 Diabetes Mellitus and Subclinical 
Hypothyroidism had a significantly higher prevalence of 
hypertriglyceridemia compared to those with a normal thyroid 
function, and the mean triglyceride value was significantly higher in 
diabetic individuals who had coexisting Subclinical Hypothyroidism. 
 
  
 
 
LIMITATIONS 
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LIMITATIONS 
1. The presence of Anti – TPO antibodies (antibodies to thyroid 
peroxidase) was not included in the study, which is shown to have 
significantly higher levels in patients with Subclinical Hypothyroidism 
in many studies 
2. The presence and absence of diabetic complications in patients with 
Subclinical Hypothyroidism was not analysed. 
3. There was a lack of similar studies performed in India to compare and 
contrast. 
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ANNEXURES 
QUESTIONNAIRE 
INCIDENCE OF SUBCLINICAL HYPOTHYROIDISM IN TYPE 2 
DIABETES MELLITUS AND ITS EFFECTS ON LIPID  
PROFILE AND HBA1C 
 
Name:  Age:   Sex:   IP Number: 
Presenting Complaints: 
Duration of Diabetes: 
Presence of vascular complications of diabetes 
 Nephropathy:    Neuropathy: 
Retinopathy:    CAD: 
 Peripheral vascular disease:  Cerebrovascular disease: 
Presence of symptoms of hypothyroidism: 
  
Current drugs taken: 
 Drugs for Diabetes: 
 Other drugs currently taking: 
Past h/o thyroid disease:    Family h/o thyroid disease: 
Recent Thyroid function tests (if any): 
Menstrual history (if female): 
Examination 
PR:   BP:   
Neck Swelling:   Examination of skin: 
CVS: 
RS: 
P/A: 
CNS: 
 Investigations: 
1. Complete Blood Count: 
Hb:   TC:   DC: P L E M 
ESR:   PCV:   Platelet: 
2. Renal Function Tests: 
S. Urea:   S.Creatinine:   
S. Na:   S. K: 
3. FBS: 
4. PPBS 
5. Thyroid Function Tests: 
 F T3: 
 F T4: 
 TSH: 
6. Complete Lipid Profile: 
S. Cholesterol:    S. Triglycerides: 
S. LDL Cholesterol:   S. HDL Cholesterol 
7. HbA1C: 
8. Others (if any): 
 
  
 
 
 
PLAGIARISM 
 
 
 
 
 
SCREEN SHOT (TURNITIN) 
 
   
INFORMATION SHEET 
 
We are conducting a study on ‘Incidence of subclinical 
hypothyroidism in patients with type 2 diabetes mellitus and its effects 
on lipid profile and HbA1C’ among patients in Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to us. 
 
 The purpose of this study is to assess the correlation of subclinical 
hypothyroidism and diabetic patients with respect to the glycemic control and 
lipid profile. We are selecting certain cases, and if you are eligible, 2 samples 
of 3 cc blood will be collected in fasting state in the morning and sent for 
investigations. These tests do not affect your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal which may 
aid in the management or treatment 
 
Signature of the Investigator           Signature of the Participant 
Date: 
Place: 
 
 
PATIENT CONSENT FORM 
Study Title : Incidence of subclinical hypothyroidism in patients with type 
2 diabetes mellitus and its effects on lipid profile and HbA1C 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification Number :  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in 
my own language ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from 
this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well-being 
or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological and biochemical tests. ❏ 
 
 
Signature/thumb impression     Signature of Investigator 
 
 
Patient’s Name and Address:     Study Investigator’s Name: 
 
Dr. Arvind Krishnakumar 
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